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ABSTRACT 
 
Jane Elizabeth Hartung: Distinct mechanisms underlie the onset and maintenance of pain linked to 
catecholamine dysregulation. 
(Under the direction of Andrea G. Nackley) 
 
A body of evidence links decreased expression and activity of catechol-o-methyltransferase 
(COMT), an enzyme that metabolizes catecholamines, with idiopathic pain conditions including 
temporomandibular joint disorder and fibromyalgia. Parallel with clinical studies, COMT inhibition 
in rodents results in increased pain, but the mechanisms required for the onset and maintenance of 
pain remained unknown. The purpose of this dissertation was to determine the downstream 
mechanisms required for COMT-dependent pain as well as to understand how environmental 
triggers can lead to decreased COMT expression. Our lab previously identified that β2- and β3ARs 
are required for the onset of COMT-dependent pain, but the molecules downstream of β2- and 
β3AR activation remained unknown. Here we examined the mechanisms required for the onset and 
maintenance of COMT-dependent pain. During the onset of pain, we found that previously 
identified β2- and β3ARs, together with circulating pro-inflammatory molecules were required for the 
onset of pain. Furthermore, release of these pro-inflammatory molecules was βAR-dependent. We 
then sought to understand if βARs and pro-inflammatory cytokines were required during the 
maintenance phase of COMT-dependent pain. We find that while βARs are important during the 
onset phase, blockade of βARs following the onset phase was not able to reverse COMT-dependent 
pain. Similarly, we did not observe differences in circulating pro-inflammatory molecules. Rather, the 
maintenance of COMT-dependent pain resulted in increased levels of activated mitogen activated 
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protein kinases (MAPKs) including p38 and extracellular regulated protein-kinase 1/2. Intrathecal 
inhibition of these molecules on day 14, after the onset of COMT-dependent pain, was able to 
reverse COMT-dependent pain, indicating that these molecules contribute to the maintenance of 
COMT-dependent pain. Finally, we sought to understand if environmental triggers could decrease 
COMT expression. We found that the inflammatory pathway nuclear factor-κB (NF-κB) is involved 
in prolonged inflammatory pain and decreased COMT expression in the brain. Taken together, these 
data point to COMT and downstream effectors play a central role in driving the onset and 
maintenance of pain. 
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Chapter 1: Introduction 
1. Introduction 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (Mersky, 2012). Its importance in 
evolution is clear: pain is one of the first sensations organisms developed in order to protect them 
from injury to their surrounding environment. The range of environmental stimuli that organisms 
encounter reflects the variety of sensations experienced: dull or sharp, fast or slow, stinging or 
tingling, aching or pulsing. This complexity has attracted clinicians, researchers, and even 
philosophers to contemplate the means by which environmental stimuli linked to pain are 
transmitted and sensed as distinct sensations. 
While acute pain is a healthy, physiological response to tissue damaging stimuli, chronic pain 
that outlasts its stimulus can have deleterious effects including tissue damage, altered immune system 
function, and a barrage of negative psychological effects. Most commonly, chronic pain patients 
exhibit exaggerated pain responses, which fall into two main categories, allodynia and hyperalgesia. 
Allodynia is defined as a painful response to a normally innocuous stimulus. Hyperalgesia is defined 
as increased pain to a normally painful stimulus.  A lack of painful stimulus and resolution of injury, 
together with the presence of allodynia and/or hyperalgesia can begin to define chronic pain 
conditions. Clinically, chronic pain is defined by the frequency and duration of symptoms. Patients 
are diagnosed when they experience pain for more than 3 months (Mujakperuo et al., 2010).  
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When patients with chronic pain seek treatment, they find that there are few effective 
treatments available. As such, chronic pain conditions have become an increasingly large problem 
for our society, costing an estimated $635 billion US dollars in treatments and lost wages (Gaskin 
and Richard, 2012). Therefore, it is imperative that researchers and clinicians work together to 
develop treatments that target the root cause of chronic pain.  
2. The Pain System: Anatomy & Structure 
2.1 Peripheral Nervous System Anatomy 
 The peripheral nervous system is the interface between our body and the environment, 
capable of sensing incoming inputs from our surroundings. As such, there are a variety of receptors 
that sense touch, pressure, vibration, temperature, and pain located on sensory neurons that 
innervate a variety of tissues: the epidermis, dermis, musculature and viscera. Upon their activation, 
sensory neurons relay information from these peripheral sites to the dorsal root ganglion and 
subsequently to the spinal cord (Basbaum et al., 2009, Purves, 2012).   
Sensory neurons are subdivided into the modalities they detect in a non-pathological and 
healthy setting by the intensity of stimuli that they detect. Sensory afferents that detect low- and 
medium-intensity stimuli include proprioceptors (which relay information regarding body position in 
space), mechanoreceptors (which detect different modalities of touch such as vibration, pressure, 
and stretch), and thermoreceptors (which detect temperature). Generally these peripheral afferent 
neurons are categorized as the Aβ fibers, medium diameter, highly-myelinated peripheral afferents 
that are capable of relaying action potential at high velocities (Purves, 2012). In contrast, high-
intensity mechanical, thermal, or chemical stimuli are detected by a subset of sensory neurons 
capable of detecting these noxious, painful stimuli, called nociceptors. Nociceptors are comprised of 
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two main groups: medium diameter, lightly myelinated Aδ-fibers and small diameter, unmyelinated 
C-fibers. Aδ-fiber afferent neurons are a group of neurons that detect and relay an action potential 
elicited by lower-threshold noxious stimuli quickly to the spinal cord. C-fiber afferent neurons are 
activated by higher-intensity noxious stimuli and because they are unmyelinated, more slowly 
conduct an action potential to the spinal cord. While Aδ- and C- fibers play the most prominent role 
in the transmission of pain signals, it should also be noted that Aβ-fibers can be activated as a result 
of peripheral sensitization. While Aβ fibers normally sense low-threshold mechanical stimuli such as 
touch, they are capable of recruiting high threshold nociceptive neurons during a non-nociceptive 
event. As a result, a normally innocuous touch stimulus can result in a painful sensation. At present, 
pain researchers hypothesize that this phenomena could be a result of either strengthened excitatory 
output by Aβ fibers or Aβ fibers acting to lower the activation threshold for high-strength stimuli 
(Basbaum et al., 2009, Purves, 2012). 
Nociceptors characterized as Aδ fiber afferent neurons have been further classified based on 
the types of noxious stimuli they detect. Type I Aδ fibers detect chemical, mechanical and relatively 
high thermal (50˚C) noxious stimuli, while Type II Aδ fibers detect noxious thermal stimuli and 
relatively high mechanical stimuli. Interestingly, Type I Aδ fibers can be sensitized to noxious 
stimuli, while Type II Aδ fibers cannot. Therefore, in the event of sensitization, Type I Aδ fibers are 
more likely to be activated in the presence of lower-threshold mechanical and thermal thresholds 
(Basbaum et al., 2009). 
C-fiber afferent neurons also include different groupings of nociceptors. While most C-
fibers can detect both mechanical and thermal stimuli, a subset of C-fibers detects thermal stimuli. 
In the presence of a sensitization event such as injury, these C-fibers become capable of sensing 
mechanical stimuli as well.  In general, C-fibers detect chemical stimuli such as menthol and 
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capsaicin as well as pruritogens such as histamine (Basbaum et al., 2009). Though most C-fibers 
detect nociception, some C-fibers are capable of detecting light touch and cooling temperatures as 
well (Burgess and Perl, 1967). 
 
Type Diameter 
(µm) 
Myelination Activation Spinal 
Innervation 
Conduction 
velocity (m/s) 
Aβ 6-12 Highly 
myelinated 
Touch (can be involved 
in pain transmission) 
Lamina III-
IV; Lamina II 
after 
nociceptive 
event 
35-75 
Aδ 1-5 Lightly 
myelinated 
Medium intensity 
(mechanical (Type I), 
temperature (Type II)) 
Lamina I-V, 
X 
5-30 
C 0.2-1.5 None High intensity (pain, 
temperature, itch, 
algogens) 
Lamina I, II 0.5-2 
 
Table 1. Description of fiber types capable of nociception.  
Adapted from table published in Chapter 4 of Neuroscience, Edition 6 (Purves, 2012). 
 
As seen in the table above, the conduction velocity of nociceptors differs depending on fiber 
diameter and axon myelination. Therefore, during a nociceptive event, Aδ fibers are involved in 
what is considered “first pain,” which is immediate and localized, while C-fibers are involved in 
“second pain,” which is longer-lasting and more diffuse (Basbaum et al., 2009). 
 Nociceptors can also be biochemically characterized into peptidergic and non-peptidergic 
populations. Peptidergic neurons release calcitonin gene-related peptide (CGRP), substance P, and 
other neuropeptides and they respond to nerve growth factor (NGF) via TrkA receptors on their 
surface. Peptidergic neurons are capable of detecting heat, itch, and mechanical stimuli, largely 
through activation of transient receptor potential channels (TRP), which are capable of detecting 
these different modalities of pain (e.g. cold, heat, chemical) (Basbaum et al., 2009, McCoy et al., 
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2013). Non-peptidergic neurons, which detect mechanical pain and itch, express c-Ret neurotrophin 
receptor, artemin, and neurturin. These non-peptidergic neurons are most-generally labeled using 
IB4 isolectin and include a further subset of neurons that express of the Mas-related G-protein 
receptors (Mrgprs) (Basbaum et al., 2009). Both Aδ and C fibers can be either peptidergic or non-
peptidergic. While research efforts have worked to further characterize the myriad populations of 
primary sensory neurons, ongoing studies continue to reveal the heterogeneity of nociceptors based 
on three main factors: the proteins they express, the stimuli they detect, and their firing patterns. 
  Aβ, Aδ, and C-fiber sensory afferent fibers converge at the dorsal root ganglion (DRG), a 
structure comprised of sensory afferent cell bodies. DRGs line the spinal cord bilaterally and contain 
a collection of afferents adjacent to the body region they innervate.   
2.2 Spinal Dorsal Horn Anatomy  
Within the central nervous system, the spinal cord contains important architecture necessary 
for the transmission and modulation of pain signals. Nociceptors terminate in the spinal cord dorsal 
horn, synapsing with second-order neurons throughout lamina I-V depending on the fiber type. 
Peptidergic C fibers terminate in lamina I and II and non-peptidergic C fibers terminate in lamina II. 
Aδ nociceptors primarily terminate in Lamina I, though they have also been found to terminate in 
lamina V and X as well. Aδ hair follicles terminate in Lamina III and IV, but also have terminals in 
lamina IIi. Table 1 above and Figure 1 below lists the sites where these nociceptors terminate (Todd, 
2010, Purves, 2012). 
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Figure 1.1. Sensory afferents terminate in different regions of the dorsal horn. 
Adapted from Todd, 2010.(Todd, 2010)  
2.3 Ascending Spinal to Supraspinal Tracts 
Second order sensory neurons originate in the dorsal horn of the spinal cord, cross over the 
spinal midline and ascend contralaterally to brain regions that interpret different aspects of qualities 
of pain (e.g., discriminative, perceptual, emotional). Researchers have characterized three main 
ascending pathways that either sense pain or are involved in the sensorimotor integration of pain: 
the spinothalamic tract, the spinobulbar tract and the spinohypothalamic tract (Purves, 2012). 
The spinothalamic tract ascends from the dorsal horn of the spinal cord and projects to 
various subregions of the thalamus, including the posterior portion of the ventral medial nucleus 
(VPN), the ventral posterior nuclei, the ventral lateral nucleus, the central lateral nucleus, the 
parafascicular nucleus, and the ventral caudal portion of the medial dorsal nucleus (Purves, 2012). 
While the anatomical locations of the projections of second order neurons to thalamic nuclei vary 
between species, or even between reference atlases within a species (Jones et al., 1987), their 
function remains largely the same: they integrate information from distinct spinal dorsal lamina and 
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project it to the brain so that both the character and intensity of pain can be perceived and 
modulated (Purves, 2012).  
The spinobulbar tract projects to the brain stem and is primarily involved in homeostatic 
regulation and nociception. Unlike the spinothalamic tract, which projects contralaterally, the 
spinobulbar tract projects bilaterally. Ascending spinobulbar fibers terminate at four main nuclei 
involved in homeostatic regulation: the periaqueductal gray, the parabrachial nucleus, the reticular 
formation of the brain stem, and brain stem sites involved in catecholamine signaling (e.g. locus 
coeruleus, ventrolateral medulla). Activation of cells that terminate at sites on the spinobulbar tract 
can lead to modulation of pain, cardiovascular changes, and alterations in autonomic regulation 
(Purves, 2012).  
Finally, the spinohypothalamic tract is proposed to play an important role in affective 
aspects of pain, including homeostatic regulation, emotional response, and endocrine regulation. The 
spinothalamic tract projects primarily to the hypothalamus, but also includes inputs to the palladium 
and nucleus accumbens. At present, there is limited evidence suggesting the spinohypothalamic tract 
exists in primates (Zhang et al., 1999) and rodents (Zhang et al., 1995). 
 
2.4 Non-neuronal Cells that Influence Pain  
While primary and secondary sensory neurons in the nervous system play the starring role in 
the transmission of pain, non-neuronal cells including glia (i.e. microglia and astrocytes), immune 
cells (i.e. myeloid- and lymphoid-derived cells), and other peripheral cells (i.e. keratinocytes, 
adipocytes, endothelial cells) may play important supporting roles in regulating the intensity and 
character of a pain signal.  
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Microglia are one type of glia derived from erythromyeloid precursor cells (the immune-
linked yolk sac cells) (Kierdorf et al., 2013, Prinz and Priller, 2014) and are considered the resident 
immune cells of the central nervous system.  They play an important role in detecting and 
responding to local inflammatory mediators known as damage-associated molecular patterns 
(DAMPs) (e.g. immune-related molecule, excitatory neurotransmitter). In the presence of a DAMP, 
a microglial cell extends its processes to detect and potentially engulf the pro-damage molecule. In 
addition, microglia will release a cocktail of trophic factors to recruit more microglia to the affected 
site to remove debris and resolve any damage. These cells are considered the first responders during 
an inflammatory event because they constantly survey their local environment for potential dangers 
(McMahon et al., 2005, Grace et al., 2014). 
 Astrocytes are another type of glia located in the nervous system but, unlike microglia, these 
cells are derived from the neuroectoderm (De Leo et al., 2006). Their function reflects their 
derivation: astrocytes regulate glutamate release and neurotransmission by adjusting concentrations 
of local K+ and Ca2+(De Leo et al., 2006). Similar to microglia, astrocytes can also release small 
inflammatory mediators known as cytokines and chemokines. Astrocytes are considered the second 
responders to an inflammatory event, as they will often act in response to pro-inflammatory 
molecule release first initiated by microglia (Gao and Ji, 2010a). 
 Both microglia and astrocytes can act to affect the neurotransmission of an action potential 
at the site of the synapse. For example, microglia alter the local environment by adjusting local 
concentrations of K+ and Cl- near the synapse or by modifying their expression of Kv1.3 or K+-Cl- 
co-transporter KCC2 (De Leo et al., 2006, Ferrini et al., 2013). As a result, microglia can modulate 
local anion/cation concentrations that can alter homeostasis required for normal neuronal 
functioning. Astrocytes can also modulate local concentrations of potassium in the central nervous 
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system. These cells serve to remove and release potassium from the synaptic cleft through the action 
of astrocytic Na/K+ ATPases (De Leo et al., 2006). 
 Thus far, I have only described the non-neuronal cells located in the peripheral and/or 
central nervous systems that affect pain. However, an ever-growing body of evidence now suggests 
that peripheral cells play a key role in the transmission and modulation of pain. The following review 
of various cell types in the periphery is not comprehensive, but rather, should serve as a starting 
point from which to understand the variety of non-neuronal cell types that may be involved in pain 
transmission, including immune cells, keratinocytes, adipocytes and endothelial cells. 
The immune system is divided into two main cell types (myeloid and lymphoid cells), which 
is based on the progenitor cell type from which they arise. Myeloid cells are derived from progenitor 
blood cells originating in the bone marrow and lymphocytes true to their name, are derived from 
lymphoid cells originating in the lymphatic system. Both cell types are essential for host defense 
against pathogens: myeloid cells regulate innate immunity and lymphoid cells regulate adaptive 
immunity. Innate immune system activation is an immediate, non-specific response that serves to 
dampen a pathogen’s strength. As the first line of defense, the innate immune system can respond 
quickly to an infection or injury by constantly circulating cells in the bloodstream that can be 
converted to immune-active cells. Myeloid-derived cells include granulocytes, such as neutrophils, 
eosinophils, basophils, dendritic cells, and monocytes. In the event of an infection that requires a 
more targeted response, the adaptive immune system is recruited to remove specific pathogens. The 
lymphoid-derived cells associated with the adaptive immune response include B-cells, T-cells, and 
natural killer cells. B- and T-cells are responsible for mounting pathogen- or damage-specific 
responses to fight off infection and resolve injury (Murphy, 2008). Both myeloid- and lymphoid-
derived cells are important to pain because they can express and release key molecules involved in 
the amplification or reduction of pain. These include a variety of small molecules, proteins, and 
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receptors important for inflammation, healing and resolution. These molecules can act directly or 
indirectly to modulate a pro-pain signal (Grace et al., 2014). 
 Other cell types, including keratinocytes, adipocytes, and endothelial cells can also influence 
pain. Keratinocytes, or skin cells, directly interface with nociceptor terminals and can result in highly 
localized chemical and electrical signals to these terminals. For example, keratinocytes can release 
pro-inflammatory molecules including cytokines to these nerve terminals, which influence the 
release of related molecules (Li et al., 2013). Furthermore, recent evidence suggests that 
keratinocytes communicate with nerve terminals through electrical signals as well. Baumbaer and 
colleagues found that activation of keratinocytes by channelrhodopsin is capable of eliciting action 
potentials from sensory neurons, including peptidergic nociceptors (Baumbauer et al., 2015). 
Adipocytes may also indirectly influence the transmission of pain through the release of IL-6, a 
known modulator of neuropathic pain (Ramer et al., 1998). Finally, emerging research implicates 
that viscerally located endothelial cells, which release ATP which can increase firing of nociceptors 
innervating visceral tissues (Xanthos and Sandkuhler, 2014). While this is not an exhaustive list of 
non-neuronal cell types involved in pain transmission, it should be noted that more and more cell 
types are being implicated in their role in pain, particularly those cells proximal to nerve terminals. 
 
3. Pathological Pain Processing 
3.1 General Overview of Pain Conditions 
Up to this point, I have described the anatomy and molecular processes that are responsible 
for acute pain. Typically, once the stimulus is removed or the tissue heals, acute pain resolves and 
the organism will return to baseline. In some instances, however, pain outlasts the stimulus as well as 
any chemical factors required for proper healing (e.g. local release of trophic factors, inflammatory 
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molecules, H+ ions) (Basbaum et al., 2009). Pain that lasts at least twelve weeks is defined as chronic 
pain. Chronic pain conditions have been subdivided into three basic categories based largely on their 
etiologies: neuropathic, inflammatory, and idiopathic pain. Neuropathic pain is defined as pain 
caused by damage to either the peripheral or central nervous system, including pain that develops as 
a result of amputation, nerve injury, cancer, and/or cancer treatment. Inflammatory pain is defined 
as pain associated with tissue injury and inflammation, caused by activation of the immune system. 
Examples of conditions categorized as inflammatory pain include arthritis (e.g. rheumatoid arthritis, 
osteoarthritis), autoimmune diseases (e.g. lupus), and colitis (Basbaum et al., 2009). Finally, 
idiopathic pain conditions do not have a clear etiology: these pain conditions are largely collected 
together by physicians because they have no clear origin, but often present a common set of 
symptoms. These symptoms include increased sensitivity to a painful mechanical and thermal stimuli 
(Gracely and Schweinhardt, 2015). Pain may be evoked or spontaneous in nature and manifest at 
multiple body sites. Based on their symptoms and their lack of etiology, the following are considered 
idiopathic pain conditions: fibromyalgia, temporomandibular joint disorder, irritable bowel 
syndrome, and vulvodynia, which will be described below based on their commonalities 
(Diatchenko et al., 2006). 
3.3 Idiopathic pain conditions 
While the etiology of idiopathic pain conditions remain largely unknown, they are 
characterized by dysfunction in the neuroendocrine system, the autonomic system, sleep, and/or 
motor function (Diatchenko et al., 2006). Researchers hypothesize that certain environmental and 
genetic factors may predispose an individual to become more vulnerable to one or more idiopathic 
pain conditions (Diatchenko et al., 2006). Because these disparate conditions may share similar 
underlying factors, diagnosis of one idiopathic pain condition increases risk of the 
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development/diagnosis of another (Lim et al., 2011). For example, patients with fibromyalgia are 
reported to be diagnosed with irritable bowel syndrome at a rate of 42-70%, while the average 
incidence rate for IBS in patients without fibromyalgia is approximately 10-16% (Veale D, 1991).  
To understand how chronic idiopathic pain conditions are established and maintained, 
research efforts are focused on identifying genetic and environmental factors that disrupt 
sympathetic tone and stress response (Mannisto and Kaakkola, 1999a, Diatchenko et al., 2005, 
Nackley et al., 2006, Orrey et al., 2012). Indeed, these potential contributors to idiopathic pain 
conditions may alter pain processing as a result of abnormal sympathetic tone during normal and 
stress-inducing situations. Given that there are few consistent and specific phenotypic and/or 
molecular markers to distinguish idiopathic pain patients, understanding the etiology of these 
diseases will serve to better treat patients. Here, I will detail how abnormalities in the sympathetic 
nervous system may affect peripheral and central sensitization of nociceptors and immune cells in 
peripheral and central nervous systems. 
3.4.1 The Sympathetic Nervous System & Pain Sensitivity: A Historical Perspective 
The autonomic nervous system, which drives the “fight or flight” response in the presence 
of stress-inducing stimuli, consists of the sympathetic and parasympathetic systems. The sympathetic 
nervous system, which primes the body for activity (to “fight”), includes peripheral and central 
nervous system inputs that drive the release of epinephrine and norepinephrine. Short-term effects 
of sympathetic nervous system activation include pupil and blood vessel dilation, redistribution of 
the blood supply from the digestive system to skeletal muscle, and increased sweating. In addition, 
short-term activation of the sympathetic nervous system generally leads to an analgesic state. 
However, long-term abnormalities in the sympathetic nervous system are associated with increased 
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pain and chronic pain conditions (McMahon, 1991, B.L. et al., 1992, Schott, 1994, Baron et al., 1999, 
Pertovaara, 2006, 2013).  
Established literature has linked sympathetic nervous system activity to the sensation of pain. 
When the sympathetic nervous system was first characterized, scientists and clinicians argued 
whether or not the sympathetic fibers innervating the periphery were only efferent, or if the system 
included both efferent and afferent fibers (Procacci and Maresca, 1987). Not until clinicians 
observed dramatic pain relief in patients with sympathetic nerve blocks or complete 
sympathectomies did the idea of a “sympathetic afferent system” gain clout in the medical and 
scientific community. Since these initial studies, a growing body of literature has linked pain, 
including chronic pain conditions such as rheumatoid arthritis, fibromyalgia, and chronic regional 
pain syndrome with altered sympathetic tone. For example, in early reports of fibromyalgia, 
originally termed “reflex sympathetic disorder,” affected individuals exhibited elevated levels of 
norepinephrine in blood plasma at baseline and following a painful stimulus (Drummon et al., 1991). 
These patients were often subject to the same sympathectomies, in the painful, affected area, which 
provided only limited relief to patients, since they were performed at discrete bodily sites. These 
were also unfavorable because blockade of the sympathetic nerve resulted in loss of function of 
sudoriferous glands in the affected area and, as a result, often led to the loss of the ability to sweat at 
the site of the sympathectomy (Bandyk et al., 2002). While these studies were first to provide a link 
between the sympathetic nervous system and pain, the pharmacological and molecular mechanisms 
that resulted in increased pain remained unknown. 
In an experimental setting, pioneering research spearheaded by Jon Levine in the mid- to 
late-1980s demonstrated the importance of sympathetic nerve terminals in the transmission of pain 
signals (Levine et al., 1985, Levine et al., 1986a, Levine et al., 1986b, Levine et al., 1988). Studies in 
rodents mirrored observations made in patient populations: increased levels of either epinephrine or 
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norepinephrine result in decreased pain thresholds (Levine et al., 1988), increased pain responsivity 
to pro-inflammatory/pro-pain molecules (Wei et al., 2015), and release of immune-related molecules 
by cells of the immune system (Nance and Sanders, 2007). Indeed, there is a rich body of literature, 
spanning from experiments conducted by Wall and colleagues in the 1970s up to now that has 
found that sympathetic input can affect pain via somatic control (vasoconstriction, immune cell 
activation) as well as by direct effects on sympathetic fiber activation (Levine et al., 1986c). These 
studies linked sympathetic activity with pain, but the underlying causes leading to altered 
sympathetic tone remained unknown.   
3.4.2 The Sympathetic Nervous System & Pain Sensitivity: The Role of COMT  
One way in which sympathetic tone may be altered is through changes in the metabolism of 
sympathetically-linked neurotransmitters, epinephrine and norepinephrine. A growing body of 
evidence demonstrates that catecholamines and pathways that regulate their bioavailability are 
altered in patients with fibromyalgia and TMD. These patients exhibit increased levels of the 
catecholamines epinephrine and norepinephrine (Light et al., 2009a) and decreased levels of the 
enzyme catechol-O-methyltransferase (COMT) (Smith et al., 2014b), one of two enzymes 
responsible for metabolizing epinephrine and norepinephrine to their inactive derivatives (the other 
related enzyme being monoamine oxidase) (Mannisto and Kaakkola, 1999a). 
COMT is ubiquitously expressed in a variety of peripheral and central nervous system tissues 
(Tunbridge et al., 2006). The gene encoding COMT includes two different promoter sites, P1 and 
P2. The P1 promoter leads to the transcription of mRNA transcript associated with the shorter 
COMT isoform, S-COMT. The P2 promoter leads to the transcription of a longer mRNA transcript, 
which can be translated to encode the S-COMT isoform as well as the MB-COMT isoform. 
(Tunbridge et al., 2006) Transcript and protein expression levels of S- and MB-COMT isoforms vary 
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across tissue types and within brain regions. Generally speaking, S-COMT is more commonly 
expressed in peripheral tissues and organs and MB-COMT is more abundant in central nervous 
system tissues. While the area of COMT protein regulation remains uncharted territory, current 
research suggests that these ratios of MB- and S-COMT protein expression is likely a result of 
differential binding of transcription factors to the P1 or P2 promoter sites (Tunbridge et al., 2006). 
In humans, single nucleotide polymorphisms in the COMT gene are linked to decreases in 
mRNA stability (Nackley et al., 2006), lower transcript and protein expression levels (Nackley et al., 
2006), and reductions in enzymatic activity (Smith et al., 2014b) which are associated with 
experimental (Diatchenko et al., 2005) and clinical pain (Diatchenko et al., 2005, McLean et al., 2011, 
Orrey et al., 2012). Based on the frequency of allele variation, it is estimated that up to two-thirds of 
chronic pain patients may carry those genetic variations that alter COMT activity (Diatchenko et al., 
2005). The first study to link COMT gene variants with pain was published by Zubieta and 
colleagues in 2003, which found that a genetic polymorphisms in the COMT gene was linked with 
reported prolonged experimental pain and elevations in sensory and affective measures of pain 
(Zubieta et al., 2003). Subsequent findings mirror these data, showing a negative correlation between 
COMT enzymatic activity and pain sensitivity. Diatchenko and colleagues reported that particular 
COMT gene variants were linked to a higher incidence of temporomandibular joint pain. Also, the 
presence of certain SNPs increased risk of developing temporomandibular joint disorder by a factor 
of 2.3 (Diatchenko et al., 2005). Similar to TMD findings, researchers found that in certain 
populations of patients with fibromyalgia, including those from Spain and Korea, fibromyalgia 
incidence was linked to COMT gene variants and high pain sensitivity (Vargas-Alarcon et al., 2007, 
Park et al., 2016). These variations in the COMT gene are important because they alter the 
expression and activity of COMT, thereby altering the metabolism of substrates of COMT, 
including catecholamines (dopamine, epinephrine, and norepinephrine) and estrogen (Nackley et al., 
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2006).  
Animal studies reflect findings in the clinic: decreased COMT activity as a result of either 
pharmacological inhibition or genetic knockout results in increased mechanical and thermal pain 
sensitivity. Given that decreased COMT activity should result in elevated levels of catecholamines, 
Nackley and colleagues looked at different catecholamine receptors that could be involved in 
nociception, including dopamine, α-adrenergic and β-adrenergic receptors. They concluded that the 
development of COMT-dependent pain is mediated through the activation of β2- and β3-adrenergic 
receptors (Nackley et al., 2007). However, the mechanisms downstream of β2 and β3-adrenergic 
receptor activation remained unclear. Furthermore, while research pointed to the importance of 
these receptors in the development of COMT-dependent pain, it is unknown whether these 
receptors are required for the maintenance of pain.  
3.4.3 The Sympathetic Nervous System & Pain Sensitivity: Beta-Adrenergic Receptors 
 An emerging body of evidence now links β2-adrenergic receptors (β2ARs) and β3-adrenergic 
receptors (β3ARs) with pain. β2ARs are located on keratinocytes, macrophages, and peripheral 
afferent neurons in the periphery as well as on microglia in the central nervous system. Activation of 
these receptors results in increased release of pro-inflammatory molecules including cytokines and 
nitric oxide as well as increased pain sensitivity. β3ARs are expressed on adipocytes where it acts as 
the prime producer of the cytokine interleukin-6 in the periphery (Tchivileva et al., 2009b) and on 
dorsal root ganglion, where it appears to play an important role in neuropathic pain development 
and maintenance (Kanno et al., 2010). Furthermore, βARs are expressed on microglia and astrocytes 
in the central nervous system, where they can exert pro-inflammatory effects downstream of βAR 
stimulation (Gharami and Das, 2004, Wohleb et al., 2011, Johnson et al., 2013). 
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 One way in which β2- and β3ARs may increase pain is through hyperalgesic priming. During 
hyperalgesic priming, epinephrine acts on small-fiber nociceptors to reduce nociceptive thresholds 
by increasing the number of action potentials elicited and reducing the latency for the first spike via 
βARs (Khasar et al., 1999b). In this sense, βAR agonists can independently increase pain by action 
on the periphery. Downstream of βAR activation, the kinases phosphokinase c (PKC), 
phosphokinase A (PKA), and extracellular-regulated kinase 1/2 may help mediate the activation of 
nociceptors through their ability to modify TTX-sensitive nociceptors (Khasar et al., 1999b, Aley et 
al., 2001). 
β-Adrenergic receptor signaling is involved in acute settings and may be important for the 
initiation of a nociceptive event (Khasar et al., 1999b). Subsequent studies have shown that βARs 
residing on nociceptors play an important role in pain. These include C-fiber afferent nociceptors 
located in the meninges (Wei et al., 2015) and keratinocytes located at the site of the nociceptor 
terminal (Li et al., 2013). Therefore, assessing the role of βAR activation on peripheral nociceptors 
may play an important role in the potentiation of pain signaling. 
3.4.4 The Sympathetic Nervous System & Pain Sensitivity: Epinephrine and Norepinephrine 
Although a body of evidence suggests that epinephrine and norepinephrine act on βARs 
residing in the periphery contribute to pain hypersensitivity, these neurotransmitters may act 
oppositely, in an anti-nociceptive manner, in the spinal cord. Descending input from α1- and α2-
adrenergic receptors reduces the transmission of nociceptive signals through three main ways: (i) 
reducing the release of excitatory neurotransmitters from peripheral nociceptors at the central 
terminal, (ii) initiating inhibitory K+ currents in postsynaptic secondary afferents, or (iii) activation of 
inhibitory interneurons residing in the dorsal spinal horn (Pertovaara, 2013). 
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Because adrenergic receptors are located on a variety of cell types that elicit different 
intracellular responses, it is not surprising that their activity in the transmission of pain is different at 
peripheral and spinal sites. A number of authors have concluded similarly. In a comprehensive 
review of catecholamine metabolism and signaling, Segall and colleagues found that epinephrine and 
norepinephrine act oppositely in the peripheral and central nervous system (Segall et al., 2012). 
Further, activity of the enzyme responsible for metabolizing these catecholamines, catechol-o-
methyltransferase (COMT), follows the same nociception pattern: intraperitoneal administration of a 
COMT inhibitor, which should presumably increase epinephrine and norepinephrine, leads to 
increased mechanical and thermal sensitivity (Nackley et al., 2007, Kambur et al., 2010); intrathecal 
administration of a COMT inhibitor does not alter nociception (Kambur, 2013). While these studies 
are highly specific to bodily site and receptor-subtype activation, their findings underline the 
importance of discriminating for site-appropriate targets that effectively alter pain sensitivity and 
their downstream targets along the pain transmission pathway.  While these studies have outlined 
how COMT may play an important role in the onset of pain, the role of COMT in the maintenance 
of pain remains unknown. 
3.5 Immune System Involvement in Pain 
3.5.1 Cytokines and Chemokines: General Overview 
 Cells involved in the innate and adaptive immune response must release chemical signals that 
indicate the need to mount an immune response. Cytokines and chemokines are small signaling 
proteins that serve a variety of roles in the immune system, including recruitment of immune cells, 
activation of intracellular pathways, and trafficking of receptors on/off the membrane (Grace et al., 
2014). Considered a specific type of cytokine, chemokines are responsible for chemotaxis, or the 
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movement of immune cells. Both chemokines and cytokines fall into the category of either pro- or 
anti-inflammatory. Pro-inflammatory cytokines ramp up an innate and/or adaptive immune 
response. Cytokines involved in the innate immune response include tumor necrosis factor-α 
(TNFα), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These molecules are the first to be released 
by macrophages after an inflammatory event or damage, signaling for the recruitment of immune 
cells and associated molecules to the site of infection. Furthermore, innate immune cytokines are 
important because they initiate an immune response: when pro-inflammatory cytokine levels remain 
high, this may activate lymphoid-derived cells to trigger an antigen-specific response by the adaptive 
immune system. Pro-inflammatory cytokines involved in the adaptive immune response include 
interleukin-2 (IL-2), interleukin-8, interleukin-18, and interferon-γ (IFNγ). These molecules play an 
important role in the activation of B- and T-cells, which drive an antigen-specific response to an 
infection. In addition, pro-inflammatory cytokines are able to upregulate particular genes involved in 
inflammation, thus creating a positive feedback loop to potentiate immune signaling/response 
(Grace et al., 2014). 
 Opposite to their pro-inflammatory counterparts, anti-inflammatory cytokines act to reduce 
inflammation, which returns the expression of pro-inflammatory cytokines to baseline levels. Anti-
inflammatory cytokines include interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-13 (IL-
13). Accumulating pre-clinical and clinical evidence suggests that impaired anti-inflammatory 
cytokine response may extend an inflammatory event and thereby potentiate pain (Milligan et al., 
2005, Grace et al., 2014, Ji et al., 2014). 
3.5.2 Cytokines and Chemokines: Their Potential Role in Pain 
 Cytokines can potentiate pain through their actions in both peripheral and central nervous 
systems. In the periphery, for example, tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β) 
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can bind to receptors expressed on peripheral nociceptor terminals to directly reduce their activation 
threshold (Binshtok et al., 2008a, Gudes et al., 2014). Furthermore, interleukin-6 (IL-6) has been 
found to be a key inducer of hyperalgesic priming, which leads to hyperactivation of nociceptors 
following an inflammatory insult and predisposes neurons to become active with prostaglandin E2 
(PGE2). Cytokines can also indirectly increase pain sensitivity. For example, TNFα can promote the 
release of a cascade of pro-inflammatory cytokines, including IL-1β, IL-6 and chemokine (C-C 
motif) ligand 2 (CCL2), which can thereby influence pain states.(Cunha et al., 2005) Furthermore, 
TNFα binds to the TNF receptor to activate intracellular cascades that upregulate pain-relevant 
genes (Grace et al., 2014). 
 In the central nervous system, pain and inflammation are potentiated by microglia and 
astrocytes that synthesize, release, and bind cytokines. Microglia express a variety of receptors that 
sense cytokines and other pro-inflammatory signals (e.g. LPS, ATP) including TLR2/4, IL-1R, 
CCR2, P2X4R, P2X13R, P2Y12R and P2X7R. TLR2/4 can stimulate p38 and extracellular regulated 
kinases (ERK). The purinergic receptors (P2X4R, P2X13R, P2Y12R and P2X7R) respond to ATP 
release following cell damage. (Grace et al., 2014) Through these receptors, then, microglia may act 
as important first mediators of central nervous system inflammation. Downstream of P2 receptor 
activation, microglia have been found to release IL-1β and initiate the intracellular p38 pathway. 
Because microglia express this wide variety of immune related molecules, it is thought that they are 
the first to respond to an inflammatory event and their activity downstream of activation results in 
the initiation of a neuroinflammatory event. After their activation, microglia are capable of releasing 
TNFα, which can bind to TNFR residing on astrocytes, leading to activation of p38 (Ji and Suter, 
2007). 
Astrocytes also express tumor necrosis factor receptor 1 (whose ligand is TNFα), 
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interleukin-18 receptor (whose ligand is IL-18), and chemokine receptor 2 (whose ligand is CCL2). 
Research on the intracellular pathways downstream of these cytokines is more limited; however, it is 
thought that activation of these astrocytically-located receptors leads to increased activation of 
mitogen activated protein kinases (MAP kinases) such as p38 and ERK1/2 as well as the 
intracellular nuclear factor-κB (NF-κB) pathway (Grace et al., 2014). Astrocytic p38 and ERK1/2 
activation can result in TNFα production (Lee et al., 2000), as well as NF-κB activation. Given that 
many intracellular events result in their activation, p38 and ERK1/2 play an important role as key 
central intracellular cascades that can control neuroinflammation and/or centrally-derived chronic 
pain states. 
In addition, previous studies in astrocyte cell lines in vitro have demonstrated that the 
cytokine TNFα can bind directly to the P2 promoter of the Comt gene and inhibit its transcription 
through activation of NF-κB.(Tchivileva et al., 2009a) Because TNFα is produced as a result of an 
inflammatory insult that can activate the NF-κB pathway, we hypothesized that inhibition of NF-κB 
decreases inflammatory pain and prevents downregulation of COMT expression while constitutive 
activation of NF-κB increases inflammatory pain and increases downregulation of COMT 
expression. 
 Pro-inflammatory molecules can also act on neurons such that they stimulate pain and/or 
produce pro-inflammatory molecules. For example, TNFRs residing on GABAergic neurons in the 
spinal dorsal horn can stimulate p38, leading to attenuated activity of GABAergic neurons and 
disinhibition of pain transmission (Zhang et al., 2010). Neurons located in the DRG also express 
toll-like receptors (TLRs), which following activation by DAMPs, can sensitize nociceptors and lead 
to local synthesis of pro-inflammatory molecules including IL-1β, CCL5, and prostaglandin E2 
(PGE2) (Grace et al., 2014).   DRG neurons can be activated by cytokines, as well: TNFα and IL-1β 
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have been found to act on TNFR and IL-1R, respectively, to initiate the p38 pathway and altering 
the activity of TTX-r sodium channels (Gudes et al., 2015).  
 While more limited research exists linking anti-inflammatory signaling molecules and their 
role in pain, emerging evidence has shown that IL-10 can act as a powerful anti-nociceptive 
molecule when administered intrathecally (Milligan et al., 2005). Furthermore, those molecules that 
promote the resolution of injury, including poly-unsaturated fatty acid derivatives such as resolvins, 
protectins and lipoxins. For example, ResolvinE1 has been shown to act through chemerin 
chemokine-like receptor 1 to inhibit activation of transient potential vanilloid receptor 1 (TRPV1), 
ERK1/2, and TNFα (Xu et al., 2013). 
3.5.3 Nitric Oxide 
 Nitric oxide (NO) is a small molecule that is involved in the transmission of pain and has 
been found to be released downstream of IL-1 and the activated nuclear factor-kappa B (NF-κB) 
inflammatory pathway (McMahon et al., 2005). NO has traditionally been viewed as a molecule 
responsible for blood vessel dilation. In the presence of NO, endothelial cells lining the blood 
vessels “relax,” thereby allowing for greater blood flow to the localized site in order to effectively 
deliver molecules responsible for injury resolution (Schmidtko et al., 2009). 
NO and nitric oxide synthases can increase pain sensitivity and initiate pro-inflammatory 
pathways. Nitric oxide is produced by nitric oxide synthases, which include three different isoforms: 
inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) and neuronal nitric 
oxide synthase (nNOS). While expression of eNOS and nNOS are largely constitutive, expression of 
iNOS can be upregulated by activation of NF-κB (Aktan, 2004). Spinal nNOS has been implicated 
as a key mediator of inflammatory and neuropathic pain, while iNOS may contribute to 
inflammatory pain (Schmidtko et al., 2009). Pain sensitivity can be heightened through NO –
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mediated activation of the enzyme guanylate cyclase which has been shown to increase neuronal 
excitability and decrease inhibition of inhibitory neurons in the central nervous system (Latremoliere 
and Woolf, 2009). NO and cytokines influence one another’s release in a feed-forward mechanism, 
such that NO stimulates cytokine release and vice versa (Holguin et al., 2004). Furthermore, because 
NO has a great propensity to bind with the free-radical superoxide (O2
-) and form the molecule 
peroxynitrite (ONOO-), prolonged elevations in NO levels may exacerbate inflammatory states and 
increase pain (Schmidtko, 2015).  
4. Summary and Aims 
Previous work by our lab demonstrated that sympathetic dysregulation following altered 
expression/activity of COMT drives pain through the activation of β2- and β3ARs. However, the 
downstream mechanisms through which β2- and β3AR activation led to increased pain remained 
unknown.  Thus, the present studies sought to reveal the downstream molecular mechanisms 
required for the onset and maintenance of pain in peripheral and central sites linked to 
catecholamine dysregulation. These studies employed the COMT inhibitor dinitrocatechol or 
OR486, which is a second-generation inhibitor similar in structure to the backbone of catechols 
(Mannisto and Kaakkola, 1999a). Because systemically administered OR486 is capable of penetrating 
the blood brain barrier, the effects of OR486 are not only in the periphery but also in the central 
nervous system. Therefore, this COMT inhibitor provided a means to mimic observations in clinical 
studies that show universal decreases in COMT expression and activity (Nackley et al., 2006, 
Nackley et al., 2007). 
The following dissertation will attempt to describe (i) the short term effects of COMT 
inhibition on pain sensitivity and pro-inflammatory molecule release via β2- and β3ARs and (ii) the 
long effects during and following chronic COMT inhibition on pain behaviors, circulating and 
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central cytokine release, and activation of glia and neurons. Here, we demonstrate that there are 
distinct mechanisms that underlie onset and maintenance of pain. Specifically, we will show that 
other molecules, independent of β2- and β3-adrenergic receptor activation play an important 
underlying role after COMT-dependent pain has been established. In addition to studying the 
downstream effects of decreased COMT inhibition, this body of work will also focus on the means 
by which COMT protein expression is decreased as a result of inflammatory insults. We report that 
NF-κB activated by an inflammatory insult results in decreased COMT protein expression in central 
nervous system tissues.  Results gathered from this research is important because it demonstrates 
that genetic factors as well as environmental events predispose an individual to decreased COMT 
expression that can result in increased pain. 
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Chapter 2: The Onset of COMT-dependent Pain 
1. Introduction 
 A growing body of literature demonstrates that catecholamines and pathways regulating their 
bioavailability influence pain. Patients with chronic pain conditions, such as fibromyalgia and 
temporomandibular disorders (TMD), exhibit increased levels of the catecholamines epinephrine 
and norepinephrine (Evaskus and Laskin, 1972, Torpy et al., 2000, Staud, 2004, Light et al., 2009a) 
as well as decreased levels of the enzyme catechol-O-methyltransferase (COMT) (Gursoy et al., 
2003, Diatchenko et al., 2005, Vargas-Alarcon et al., 2007), which metabolizes epinephrine and 
norepinephrine to their inactive derivatives (Mannisto and Kaakkola, 1999a). Consistent with these 
findings, animal studies show that epinephrine administration (Coderre et al., 1990, Khasar et al., 
1999a, Khasar et al., 1999b) or COMT inhibition (Nackley et al., 2007, Kambur et al., 2010) 
increases mechanical and thermal hyperalgesia. Pharmacologic studies reveal that COMT-dependent 
pain, decreased COMT resulting in enhanced sensitivity, is mediated via both β2- and β3-adrenergic 
receptors (β2ARs β3ARs). While antagonism of either β2- or β3ARs block acute COMT-dependent 
pain, this enhanced sensitivity was completely blocked by antagonizing both β2- and β3ARs (Nackley 
et al., 2007). 
 β2ARs and β3ARs are G-protein coupled receptors expressed in peripheral, spinal, and 
supraspinal sites involved in pain transmission. Stimulation of β2- or β3ARs on peripheral afferents 
directly sensitize nociceptors (Khasar et al., 1999a, Sun et al., 2006) and produce allodynia (Kanno et 
al., 2010) through activation of intracellular kinases. Additionally, stimulation of β2- or β3ARs 
indirectly enhance pain transmission through the release of pro-inflammatory molecules including 
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nitric oxide and cytokines (Maimone et al., 1993, Akimoto et al., 2002, Frost et al., 2004, Furlan et 
al., 2005, Canova et al., 2006, Tan et al., 2007, Hodges et al., 2008, Figueroa et al., 2009, Tchivileva et 
al., 2009b).  
Nitric oxide (NO) is a gaseous molecule whose production by NO synthases can be induced 
by stimulation of β2ARs on endothelial cells, smooth muscle, sympathetic afferent neurons, and 
macrophages (Akimoto et al., 2002, Hodges et al., 2008, Figueroa et al., 2009) or stimulation of 
β3ARs on adipocytes and fibroblasts (Furlan et al., 2005, Canova et al., 2006).  Following release, 
NO lowers the firing threshold of nociceptors (Aley et al., 1998, Boehning and Snyder, 2003) to 
enhance experimental inflammatory and neuropathic pain (Omote et al., 2001, Holguin et al., 2004, 
Kuboyama et al., 2011). Furthermore, NO can stimulate release of additional molecules involved in 
nociception, including pro-inflammatory cytokines (Holguin et al., 2004, Chen et al., 2010). 
Pro-inflammatory cytokines linked to pain include tumor necrosis factor α (TNFα), 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2, MCP-1). β2- 
and β3AR stimulation promotes the production and release of TNFα, IL-1β, IL-6, and CCL2 
(Maimone et al., 1993, Frost et al., 2004, Tan et al., 2007, Tchivileva et al., 2009b, Roth Flach et al., 
2013). Signaling by TNFα, IL-1β, and IL-6 lead to lower nociceptor firing thresholds and enhanced 
pain sensitivity (Obreja et al., 2002, Obreja et al., 2005, Binshtok et al., 2008b, Czeschik et al., 2008). 
Similarly, CCL2 enhances nociceptor firing in models of neuropathic pain (Sun et al., 2006, Jung et 
al., 2008).  
Of note, NO and cytokines influence one another’s release. NO drives the production and 
release of cytokines such as TNFα and IL-1β (Jongeneel, 1995, Watkins et al., 1999, Chen et al., 
2010, Cury et al., 2011), while cytokines can upregulate NO synthase expression and promote NO 
release (Lamas et al., 1991, Teixeira et al., 1993, Grabowski et al., 1996, Sung et al., 2005). This 
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positive feedback loop may contribute to the development and/or maintenance of pain (Cury et al., 
2011). While NO and cytokines are released following β2- and β3AR stimulation and are linked with 
pain, their role in COMT-dependent pain has not been established. 
To investigate the role of NO and cytokines in COMT-dependent pain mediated by β2- and 
β3ARs, we measured plasma NO and cytokines following administration of a COMT inhibitor in the 
presence or absence of β2- and β3AR antagonists.  Additionally, we measured mechanical and 
thermal pain sensitivity following COMT inhibition in the presence or absence of a NO synthase 
inhibitor or TNFα, IL-1β, IL-6, or CCL2 neutralizing antibodies. Our results demonstrate that (1) 
COMT-dependent pain is accompanied by increases in peripheral NO derivatives and cytokines 
mediated by β2- and β3ARs, (2) inhibition of NO synthesis and neutralization of the innate immunity 
cytokines TNFα, IL-1β, IL-6 block COMT-dependent pain, and (3) NO and cytokines potentiate 
one another’s biosynthesis, such that NO promotes the release of TNFα, IL-1β, IL-6, and CCL2 
while TNFα and IL-6 promote NO release.  
2. Materials and Methods: 
2.1 Subjec ts  
 Adult male Sprague Dawley rats (Charles River Laboratories, Raleigh, NC) were used in all 
experiments. Rats weighed between 215-265 g for β2- and β3AR antagonism and NO synthase 
inhibition experiments and between 315-360 g for cytokine neutralization experiments.  
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2.2 Drugs and chemicals 
 As described in Nackley et al., 2007 (Nackley et al., 2007), OR486 was dissolved in DMSO 
and diluted in 0.9% saline (3:2).  ICI18551, SR59230A, and L-NAME were dissolved in DMSO and 
0.9% saline (1:4). Functional grade antibodies against tumor necrosis factor α (α-TNFα), 
interleukin-1β (α-IL-1β), interleukin-6 (α-IL-6), chemokine (C-C motif) ligand 2 (α-CCL2) or IgG 
control were dissolved in 0.9% saline. OR486, ICI118,551, and SR59230A were purchased from 
Tocris (Ellisville, MO). L-NAME was purchased from Sigma-Aldrich (St. Louis, MO). Neutralizing 
antibodies against TNFα, IL-1β, CCL2 and Armenian hamster IgG controls were purchased from 
eBiosciences (San Diego, CA), while the antibody against IL-6 (polyclonal goat IgG) was purchased 
from R&D Systems (Minneapolis, MN). 
2.3 General Experimental Conditions 
 Animals were handled and habituated for 4 days prior to testing day.  On testing day, animals 
were habituated to the environment for 10-15 minutes and then stable baseline responses to 
mechanical or thermal stimuli were established in separate groups of rats. Following baseline testing, 
animals received drug treatment and behavior was reassessed. Responses to mechanical stimuli were 
reassessed at 30, 75 and 120 minutes following OR486 and responses to thermal heat were 
reassessed at 120 minutes following OR486. 
 Experimenter was blinded to first and second experimental treatments. Animals were 
grouped separately based upon the three types of treatments used: β2- and β3AR antagonists, NOS 
inhibitors, and neutralizing antibodies. 
 We first sought to determine if COMT-dependent pain is accompanied by increases in NO 
and cytokines and if this was mediated by β2- and β3ARs. Separate groups of animals received 
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intraperitoneal (i.p.) ICI118,551 (0.5mg/kg) together with SR59230A (5.0mg/kg) or vehicle 30 
minutes before i.p. OR486 (30 mg/kg) or vehicle.  
 We then sought to elucidate the role of NO and cytokines in driving COMT-dependent 
pain. To determine if NO production was required for the development of COMT-dependent pain, 
separate groups of animals received i.p L-NAME (30 mg/kg) or vehicle 30 min before i.p. OR486 
(30 mg/kg) or vehicle. L-NAME dosage was based on that used in Kuboyama et al., 2011 
(Kuboyama et al., 2011).  To determine if cytokine action was required for the development of 
COMT-dependent pain, separate groups of animals received intravenous (i.v.) α-TNFα (75 ug), α-
IL-1β (75 ug), α-IL-6 (75 ug), α-CCL2 (75 ug) or IgG control (75 ug) dissolved in 250 µL 0.9% 
saline 2h prior to i.p. OR486 (30 mg/kg) or vehicle. Dosages of neutralizing antibody were 
determined by two sources: previous reports using neutralizing antibodies and the effective 
neutralizing dose that would neutralize cytokines at the average dosages we observed at 180 minutes 
following OR486 administration (Lindenlaub et al., 2000, Tan et al., 2007). We chose to administer 
the antibodies by i.v. injection to optimize the circulation of the antibody in a relatively short 
amount of time.  
 Finally, we sought to establish if NO and cytokines influenced one another’s biosynthesis. 
To determine if NO synthesis was required for cytokine release, plasma collected from animals in 
the L-NAME experiments was measured for levels of TNFα, IL-1β, IL-6 and CCL2.  To determine 
if cytokine action was required for NO release, plasma from animals receiving neutralizing 
antibodies against TNFα, IL-1β, IL-6, and CCL2 was measured for levels of total nitrite (nitrite and 
nitrate). 
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Figure 2.1. Timeline of administered treatments used in this study.  
The COMT inhibitor OR486 or vehicle were administered in the presence or absence of the β2- and 
β3-adrenergic receptor antagonists ICI118,551 and SR59230A, the NO synthase inhibitor L-NAME, 
or neutralizing antibodies against TNFα, IL-1β , IL-6, or CCL2. 
2.4 Assessment of Mechanical Allodynia and Mechanical Hyperalgesia 
 Paw withdrawal threshold was measured using the von Frey up-down method, as described 
in Nackley et al., 2007 and below. Nine calibrated von Frey monofilaments (bending forces of 0.40, 
0.68, 1.1, 2.1, 3.4, 5.7, 8.4, 13.2, and 25.0 g; Stoelting) with equal logarithmic spacing between 
filaments were applied to the plantar surface of the hind paw. A series of six applications of 
monofilaments with varying gram forces was applied for 3 s to the plantar surface of the hindpaw. 
Testing began with the middle filament in the series (3.4 g). If the response included the withdrawal 
of the hindpaw, an incrementally lower filament was applied. In the absence of a paw withdrawal, an 
incrementally higher filament was applied. These data were entered into Paw Flick module within 
the National Instruments LabVIEW 2.0 (Austin, TX) software. A logarithmic algorithm accounted 
for the order and number of withdrawal responses as well as the gram force of the final filament to 
calculate mechanical threshold, the gram force that would elicit paw withdrawal in 50% of trials (10 
[Xf+kδ]/ 10,000, where Xf = value (in log units) of the final von Frey hair used; k = tabular value of 
positive and negative responses, and δ = mean difference (in log units) between stimuli). Mechanical 
 31 
allodynia was defined as a heightened response to a normally innocuous stimulus and was 
determined as a significant decrease in paw withdrawal threshold from baseline. 
 After determining paw withdrawal threshold, paw withdrawal frequency to a noxious von 
Frey monofilament was assessed. The highest gram force filament (25.0 g) was applied to the hind 
paw 10 times.  Stimulus was applied for 1s followed by a 1s interval without a stimulus. The number 
of paw withdrawals was recorded for each hindpaw. Mechanical hyperalgesia was defined as an 
increase in the number of paw withdrawals to a noxious mechanical stimulus from baseline. 
2.5 Assessment of Thermal Hyperalgesia 
 Thermal hyperalgesia was measured using the radiant method by applying radiant heat to the 
hind paw as described in Hargreaves et al., 1988 (Hargreaves et al., 1988). Animals were placed in 
individual Plexiglass chambers and habituated for approximately 10 minutes. Following habituation, 
a radiant beam of light was applied to the plantar surface of the rat hind paw through a glass floor 
heated to 30˚C. Latencies of paw withdrawal from the heat stimulus were recorded in duplicate.  If 
the second paw withdrawal latency was not within +4 seconds of the first withdrawal latency, then a 
third measure was recorded. The two latencies closest in value were averaged and included in the 
analysis. Thermal hyperalgesia was defined as a decrease in paw withdrawal latency to a noxious 
thermal stimulus compared to baseline. 
2.6 Tissue Collection 
 Following behavioral testing, animals were euthanized by injection of 0.5 mL Fatal-Plus 
(Vortech Pharmaceuticals, Dearborn, MI). Arterial blood was collected and placed in EDTA plasma 
tubes, then centrifuged for 15 minutes at 15,000 x g.  Following collection, plasma was stored at -
80˚C.  
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2.7 Measurement of NO Derivatives 
 To measure nitrite, NO in blood plasma was assessed using the Griess Reaction (Promega, 
Madison, WI). To measure total nitrite (nitrite and nitrate), NO in blood plasma was assessed by kit 
from R&D Systems (Minneapolis, MN). 
2.8 Measurement of Cytokines  
 To determine if COMT inhibition raised TNFα plasma levels downstream of β2- and β3AR 
stimulation, plasma TNFα was measured by the UNC Proteomics/Immunotechnologies Core using 
ELISA kits from Biosource (Camarillo, CA). To determine if COMT inhibition raised TNFα plasma 
levels downstream of NO production, plasma TNFα was measured by chemiluminescent ELISA 
(Life Technologies Carlsbad, CA) due to discontinuation of aforementioned Biosource kit. IL-1β 
was measured by the UNC Cytokine Analysis Facility using the Luminex Rat Cytokine Multiplex 
Array from R&D Systems (Minneapolis, MN). IL-6 and CCL2 were measured by ELISA 
(eBioscience, San Diego, CA; R&D Systems, Minneapolis, MN, respectively). Selected ELISAs and 
multiplex were based upon minimum assay range and analyte sensitivity. All plasma samples were 
diluted at 2x. 
2.9 Statistical Analysis 
 All behavioral data were analyzed using a t-test to verify that there were no significant 
differences in baseline values. Baseline mechanical allodynia values did differ in two groups and were 
normalized by adding the difference between the average baseline threshold values and the average 
baseline threshold value for all groups to each animal at each time point. Mechanical allodynia and 
hyperalgesia data were analyzed by two-way analysis of variance (ANOVA). Thermal hyperalgesia 
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and molecular data were analyzed using a one-way ANOVA. Post-hoc comparisons were performed 
using the Bonferroni test and were corrected for multiple testing. P< 0.05 was considered to be 
statistically significant.  
3. Results 
3.1 COMT inhibition results in increased pain sensitivity and production of pro-inflammatory mediators via β2- and 
β3ARs 
To recapitulate our lab’s previous results demonstrating that acute COMT-dependent pain is 
mediated by both β2- and β3ARs, we measured pain behavior in animals receiving the β2AR 
antagonist ICI118,551 together with the β3AR antagonist SR59230A prior to the COMT inhibitor 
OR486. As expected, animals receiving OR486 exhibited mechanical allodynia (F3,137=9.223, P < 
0.0001; Fig. 2A), mechanical hyperalgesia (F3,139= 11.45, P < 0.0001; Fig. 2B) and thermal 
hyperalgesia (F3, 54=5.336, P < 0.003; Fig. 2C) compared to those receiving vehicle. COMT-
dependent increases in pain sensitivity were observed 30 to 120 min following drug administration 
and were completely blocked by co-administration of β2- and β3AR antagonists.  
Following the conclusion of behavioral experiments, blood plasma was collected to measure 
circulating levels of NO derivatives, TNFα, IL-1β, IL-6, and CCL2. Animals receiving OR486 
exhibited increased levels of nitrite (F3, 23= 3.929, P <0.03; Fig. 2D), TNFα (F2,18=5.663, P<0.02; Fig. 
2E), IL-1β (F3,27=3.428, P<0.04; Fig. 2F), IL-6 (F3,19=1.354, P=0.2; Fig. 2G), and CCL2 (F3,27=3.569, 
P <0.03; Fig. 2H). COMT-dependent increases in nitrite and cytokines were completely blocked by 
co-administration of ICI118,551 and SR59230A. 
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Figure 2.2. COMT inhibition increases pain, NO derivatives, and cytokines via β2,3ARs.   
Animals receiving OR486 (30 mg/kg) exhibit (A) mechanical allodynia, (B) mechanical hyperalgesia, 
and (C) thermal hyperalgesia, as well as increased circulating levels of (D) nitrite, (E) TNFα, (F) 
IL-1β, (G) IL-6, and (H) CCL2. COMT-dependent increases in pain, nitrite, and cytokines were 
completely blocked by co-administration of ICI118,551 (0.5 mg/kg) and SR59230A (5.0mg/kg). 
N=6-10 per group. Data are mean + SEM. *P<0.05, **P<0.01, ***P<0.001 different from 
Veh/Veh, #P<0.05 different ICI+SR/Veh and ICI+SR/OR486.  
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3.2 NO synthase inhibition and cytokine neutralization prevent COMT-dependent pain 
As NO and cytokines are released following stimulation of β2- and β3ARs and have been 
implicated in the development of pain in other models, we sought to determine their role in the 
development of acute COMT-dependent pain. To first evaluate the contribution of NO synthesis, 
we measured pain behavior in separate groups of animals that received the NO synthase inhibitor L-
NAME or vehicle 30 min prior to OR486. Administration of L-NAME prior to OR486 blocked the 
development of mechanical allodynia (F3,138=5.195, P<0.003; Fig. 3A),  mechanical hyperalgesia 
(F3,138=5.195, P<0.003; Fig. 3B), and thermal hyperalgesia (F3,54=6.337, P<0.001; Fig. 3C). Therefore, 
NO production by NO synthases is required for the development of COMT-dependent increases in 
mechanical and thermal pain. 
 
Figure 2.3. Inhibition of NO synthesis prevents COMT-dependent pain.  
Administration of the universal nitric oxide synthase inhibitor L-NAME (30 mg/kg) prior to OR486 
(30 mg/kg) normalized (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal 
hyperalgesia. N=8-10 per group. Data are mean + SEM. *P<0.05, **P<0.01, ***P<0.001 different 
from Veh/Veh. 
 
To next evaluate the individual contributions of TNFα, IL-1β, IL-6, and CCL2 to acute COMT-
dependent pain, we measured pain behavior in separate groups of animals receiving neutralizing 
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antibodies against TNFα, IL-1β, IL-6, and CCL2 or control IgG prior to OR486. Results show that 
neutralization of the innate immunity cytokines (TNFα, IL-1β, and IL-6), but not CCL2, prevented 
OR486-dependent increases in mechanical and thermal pain. Administration of α-TNFα 
(F3,84=10.71, P<0.0001; Fig. 4A), α-IL-1β (F3,83=19.34, P<0.0001; Fig. 4D), and α-IL-6 (F3,87=10.96, 
P<0.0001; Fig. 4G) blocked mechanical allodynia. Additionally, pretreatment with α-TNFα 
(F3,89=30.95, P<0.0001; Fig. 3B), α-IL-1β (F3,89=29.72, P<0.0001; Fig. 4E), and α-IL-6 (F3,93=23.33, 
P<0.0001; Fig. 4H) blocked  mechanical hyperalgesia. Finally, α-TNFα (F3,47=5.312, P<0.004; Fig. 
4C), α-IL-1β (α-IL-1β: F3,49=5.639, P<0.002; Fig. 4F), and α-IL-6 (F3,48=3.339, P<0.003; Fig. 4I) 
blocked thermal hyperalgesia at 120 min. However, α-CCL2 was not effective at blocking 
mechanical allodynia (Fig. 4J), mechanical hyperalgesia (Fig. 4K) or thermal hyperalgesia (Fig. 4L). 
Therefore, the innate immunity cytokines TNFα, IL-1β, and IL-6 are required for the development 
of COMT-dependent pain. 
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Figure 2.4. Neutralization of TNFα, IL-1β, and IL-6, but not CCL2, blocks COMT-dependent pain.  
Administration of α-TNFα (75 µg), α-IL-1β (75 µg), or α-IL-6 (75 µg) prior to OR486 (30 mg/kg) 
normalized (A, D, G) mechanical allodynia, (B, E, H) mechanical hyperalgesia, and (C, F, I) 
thermal hyperalgesia. (J-L) Administration of α-CCL2 failed to block OR486-induced increases in 
mechanical and thermal pain. N=6-8 per group. Data are mean + SEM. *P<0.05, **P<0.01, 
***P<0.001 different from Control IgG/Veh. #P<0.05 different from α-TNFα/Veh and α-
TNFα/OR486.  
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3.3 Interplay between NO and cytokine protein expression in COMT-dependent pain 
We then sought to determine if these pro-inflammatory molecules could influence the synthesis 
and release of one another downstream of β2- and β3AR stimulation. Blood plasma was collected 
from animals that received L-NAME or cytokine neutralizing antibodies prior to OR486 and 
peripheral levels of NO derivatives and cytokines were measured. In NO inhibition experiments, 
levels of TNFα, IL-1β, IL-6, and CCL2 were elevated in animals receiving vehicle prior to OR486. 
Pre-administration of L-NAME blocked OR486-mediated increases in TNFα (F3,39=0.2989, P<0.83; 
Fig. 5A), IL-1β (F3,27=3.255, P<0.04; Fig. 5B), IL-6 (F3,18=1.354, P<0.3; Fig. 5C), and CCL2 
(F3,27=2.761, P=0.06; Fig. 5D).   
In cytokine neutralization experiments, total nitrite (nitrite + nitrate) concentrations in blood 
plasma were elevated in animals receiving control IgG prior to OR486. Pre-administration of α-
TNFα (F3,21=3.230, P<0.05; Fig. 6A) or  α-IL-6 (F3,22=3.772, P<0.03; Fig. 6C) prior to OR486 
blocked elevations in total nitrite. However, pre-administration of α-Il-1β (Fig. 6B) or α-CCL2 (Fig. 
6D) failed to block OR486-mediated increases in total nitrite levels. Thus, NO and cytokines drive 
one another’s biosynthesis. 
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Figure 2.5. Inhibition of NO synthesis prevents COMT-dependent increases in cytokines.  
Administration of the nitric oxide synthase inhibitor L-NAME (30 mg/kg) prior to OR486 (30 
mg/kg) blocked increases in circulating levels of (A) TNFα, (B) IL-1β, (C) IL-6, and (D) CCL2. 
N=6-10 per group. *P<0.05 different from Veh/Veh. 
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Figure 2.6. Neutralization of TNFα and IL-6 prevents COMT- dependent increases in NO.  
OR486-induced increases in total nitrite (nitrite and nitrate) were blocked by pretreatment with (A) 
α-TNFα (75 µg) or (C) α-IL-6 (75 µg), but not (B) α-IL-1β (75 µg) or (D) α-CCL2 (75 µg). N=6-8 
per group. Data are mean + SEM. %P<0.05 different from α-TNFα/Veh, #P< 0.05 different from 
α-IL-6/Veh and α-IL-6/OR486. 
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4. Discussion 
Our laboratory previously demonstrated that COMT inhibition produces remarkable 
increases in mechanical and thermal pain sensitivity through stimulation of both β2- and β3ARs 
(Nackley et al., 2007). However, the molecular mechanisms whereby these receptors drive COMT-
dependent pain have remained unknown. Here, we identify NO, TNFα, IL-1β, and IL-6 as 
molecules downstream of β2- and β3AR stimulation that are critical for the development of pain 
associated with decreased COMT activity. Furthermore, we demonstrate that NO and cytokines act 
in a positive feedback loop to induce one another’s biosynthesis. 
4.1 Role of Nitric Oxide in COMT-dependent Pain  
NO is a paracrine signaling molecule produced by three different nitric oxide synthase 
isoforms: neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2), and endothelial NOS 
(eNOS, NOS3). While previous studies have linked NO to inflammatory and neuropathic pain, here 
we provide the first demonstration that NO contributes to COMT-dependent pain. Specifically, we 
found that stimulation of β2- and β3ARs following COMT inhibition resulted in increased levels of 
NO derivatives and that inhibition of NO synthesis with L-NAME prevented the development of 
COMT-dependent mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia. These 
findings are in line with results from clinical and animal studies showing NO is upregulated 
following injury and inflammation (Omote et al., 2001, Holguin et al., 2004, McMahon et al., 2005, 
Schmidtko et al., 2009, Chen et al., 2010, Cury et al., 2011, Kuboyama et al., 2011) and that genetic 
or pharmacologic blockade of NO can suppress pain in these models (Omote et al., 2001, Holguin 
et al., 2004, Marchand et al., 2005, Chen et al., 2010, Ramachandran et al., 2010, Kuboyama et al., 
2011). 
NO is able to produce pain through several mechanisms, including the canonical stimulation 
of cyclic guanylyl monophosphate (cGMP), which can enhance activity of Ca2+-activated K+ 
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channels and, thus, the firing rate of nociceptors. NO can also stimulate cyclic adenosine 
monophosphate (cAMP)-mediated production of pro-pain prostaglandins (PGE2) that sensitize 
primary afferents (Aley et al., 1998, Boehning and Snyder, 2003). Furthermore, NO can stimulate 
cAMP production through S-nitrosylation of adenylate cyclase and the phosphorylation of cAMP 
response element binding (CREB) protein by cGMP. Activation of CREB leads to enhanced 
expression of cytokines such as IL-1β and TNFα (Jongeneel, 1995, Watkins et al., 1999, Chen et al., 
2010). While others have linked NO production with β2- and β3AR stimulation in the context of 
inflammation (Akimoto et al., 2002, Tan et al., 2007, Hodges et al., 2008, Figueroa et al., 2009), this 
is the first demonstration that NO synthesis is critical for COMT-dependent pain and cytokine 
production. 
4.2 Role of Pro-Inflammatory Cytokines in COMT-dependent Pain 
 TNFα, IL-1β, and IL-6 are innate immunity cytokines, considered to be the first-responders 
to injury or pro-inflammatory events. In an acute setting, these cytokines convey a protective 
advantage by promoting wound healing (Dinarello et al., 1990). However, sustained elevations of 
these cytokines can promote tissue damage and pain. Here, we found that COMT inhibition led to 
the release of TNFα, IL-1β, IL-6, and CCL2 mediated by β2- and β3ARs. We also found that 
neutralization of the innate immunity cytokines TNFα, IL-1β and IL-6, but not CCL2, prevented 
COMT-dependent mechanical and thermal sensitivity.  
Stimulation of β2- and β3ARs located on cells in the periphery and central nervous system 
can enhance production of TNFα, IL-1β, IL-6, and CCL2 (Nance and Sanders, 2007, Tan et al., 
2007, Johnson et al., 2008, Tchivileva et al., 2009b, Wang et al., 2010, Wohleb et al., 2011, Johnson 
et al., 2013, Li et al., 2013), which can then enhance pain sensitivity. Elevations in these cytokines 
have been found in local synovial joint fluid from patients with TMD (Kubota et al., 1998) and in 
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blood from patients with fibromyalgia and migraine (Sarchielli et al., 2006a, Slade et al., 2011, Uzar 
et al., 2011). Neutralization of TNFα, IL-1β, and IL-6 reduces the development of allodynia and 
hyperalgesia in models of neuropathic pain (Lindenlaub et al., 2000, Sommer et al., 2001, Obreja et 
al., 2005, Binshtok et al., 2008b), suggesting that these cytokines are critical for pain.  
Cytokines downstream of β2- and β3AR stimulation likely drive COMT-dependent pain 
through direct and indirect mechanisms. Previous studies have demonstrated that TNFα, IL-1β and 
IL-6 can bind to their respective receptors on nerve terminals to directly sensitize peripheral 
nociceptors (Obreja et al., 2002, Obreja et al., 2005, Binshtok et al., 2008b, Czeschik et al., 2008). 
TNFα can also drive sensitization of nociceptors through receptor-independent increases in the 
production of other pro-inflammatory cytokines. Cunha and colleagues found that α-TNFα blocked 
CFA-induced increases in pain and IL-1β production (Cunha et al., 2005).  They speculated that 
TNFα acts as the first cytokine in the cascade to stimulate the sequential release of IL-6, IL-1β, and 
PGE2.  
In contrast to the innate immunity cytokines, administration of α-CCL2 did not prevent the 
development of COMT-dependent pain. This may be due to one of two possibilities: (1) that higher 
dosages of a-CCL2 may reduce COMT-dependent pain and NO release or (2) that CCL2 is critical 
for the maintenance versus the development of pain. Previous studies have shown that CCL2 
recruitment of monocytes and neutrophils to the site of injury occurs at later time points after 2 
hours (Pflucke et al., 2013). Furthermore, CCL2 is released from spinal dorsal horn astrocytes, 
which are glial cells involved in the maintenance of pain states (Gao and Ji, 2010b).  
4.3 Interplay between NO and Cytokines in COMT-dependent pain 
Mounting evidence suggests that a positive feedback loop exists between NO and cytokines, 
such that they can induce one another’s biosynthesis. Here, we found that inhibition of NO 
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synthesis effectively blocked COMT-dependent increases in TNFα, IL-1β, IL-6 and CCL2, while 
neutralization of TNFα and IL-6 blocked COMT-dependent increases in the production of NO 
derivatives. Disruption of NO, TNFα or IL-6 signaling reduces the pro-inflammatory feedback 
mechanism important for COMT-dependent pain. This synergistic relationship between NO and 
cytokines has been observed as a key characteristic of inflammation. NO has long been known to 
act as a putative molecule dictating macrophage trafficking (Boehning and Snyder, 2003) and 
cytokine production and release (Holguin et al., 2004, Chen et al., 2010, Kuboyama et al., 2011). 
Furthermore, NO can influence the transcription of cytokines such as TNFα (Jongeneel, 1995) and 
IL-1β (Watkins et al., 1999). Cytokines can also influence NO synthesis, as TNFα, IL-1β and IL-6 
have been found to increase NOS transcription by directly binding to the promoter or by 
stimulating p38-MAPK (Lamas et al., 1991, Lowenstein et al., 1993, Sung et al., 2005). The collective 
work from our lab and others demonstrates that NO and cytokines influence one another’s 
biosynthesis and suggest that it is the ‘net effect’ of these molecules that ultimately influences pain.   
4.4 Greater Implications and Clinical Relevance  
As observed here, decreased COMT activity enhances pain by increasing the production of 
NO and cytokines via β2- and β3ARs. Evidence suggests that peripherally delivered neutralizing 
antibodies do not cross the blood brain barrier (Wittrup and Verdine, 2012), though evidence for 
blood-brain trafficking is less clear for L-NAME. While we observed that the release of pro-
inflammatory molecules contribute to acute COMT-dependent pain, it is possible that there are also 
mechanisms of pain transmission and transduction occurring in spinal and supraspinal sites. Taken 
together, we believe that acute COMT-dependent pain is driven largely in the periphery.  
Genetic variants resulting in decreased COMT activity have been associated with chronic 
pain conditions such as fibromyalgia [24] and TMD (Diatchenko et al., 2005), which are linked to 
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increased levels of catecholamines (Evaskus and Laskin, 1972, Torpy et al., 2000) and production of 
pro-inflammatory molecules (Larson et al., 2000, Di Franco et al., 2010, Bote et al., 2012). 
Specifically, patients with fibromyalgia (Larson et al., 2000, Bote et al., 2012) and TMD (Shafer et al., 
1994, Kubota et al., 1998, Slade et al., 2011, Fan et al., 2012) exhibit higher levels of NO derivatives 
(e.g. nitrite and nitrate) and cytokines such as TNFα, IL-1β, IL-6, and CCL2. Recent reports suggest 
that β-adrenergic mechanisms involved in COMT-dependent pain may overlap with those observed 
in complex regional pain syndrome (Li et al., 2013), which is also linked to stimulation of βARs and 
increased production of pro-inflammatory cytokines. While this study identifies the molecules 
contributing to the development of COMT-dependent pain by pre-emptively blocking the action of 
β2- and β3ARs, NO synthases, and cytokines, future studies will identify processes required for the 
maintenance of COMT-dependent pain following its induction. Therefore, we may more closely 
mimic the treatment chronic pain conditions following their development. Based on these and 
future studies, βAR antagonist therapy used to mitigate catecholamine signaling and alleviate pain in 
patients with fibromyalgia and TMD (Wood et al., 2005, Light et al., 2009a, Tchivileva et al., 2010) 
may benefit other patient populations suffering from pain conditions of shared etiology.  
5. Conclusions.   
 In conclusion, these findings elucidate the molecules downstream of β2- and β3ARs that 
drive acute COMT-dependent pain. Elevated levels of norepinephrine/epinephrine, resulting from 
decreased COMT activity, stimulate β2- and β3ARs to promote the release of NO and the innate 
immunity cytokines TNFα, IL-1β, and IL-6, which in turn produce heightened pain sensitivity. The 
chemokine CCL2 was elevated in COMT-deficient animals, but its blockade did not prevent the 
development of acute COMT-dependent pain. Additionally, we found that NO and innate immunity 
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cytokines function in a positive feedback loop to strengthen their own biosynthesis. This 
amplification mechanism may form the basis for the development of prolonged hypersensitive pain 
states. Finally, these data suggest that patients suffering from pain conditions associated with 
abnormalities in catecholamine signaling may benefit from therapeutics that selectively regulate the 
activity of β2- and β3ARs and downstream effectors. 
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Chapter 3: The Maintenance of COMT-dependent Pain 
1. Introduction 
Chronic pain disorders such as fibromyalgia and temporomandibular disorders (TMD) 
negatively impact the lives of millions of Americans and cost $635 billion in treatment and lost 
wages (Gaskin and Richard, 2012).  In line with an established literature linking sympathetic nervous 
system activity and chronic pain (McMahon, 1991, Baron et al., 1999, Torpy et al., 2000, Martinez-
Lavin et al., 2002, Finan et al., 2011), a growing body of evidence demonstrates that catecholamines 
and pathways that regulate their bioavailability are altered in patients with fibromyalgia and TMD. 
These patients exhibit increased levels of the catecholamines epinephrine and norepinephrine 
(Baron et al., 1999, Mannisto and Kaakkola, 1999b, Torpy et al., 2000, Martinez-Lavin et al., 2002), 
and decreased levels of the enzyme catechol-O-methyltransferase (COMT), which metabolizes 
epinephrine and norepinephrine to their inactive derivatives (Mannisto and Kaakkola, 1999a). Based 
on the frequency of allele variation, it is estimated that up to two-thirds of chronic pain patients may 
carry genetic variations that alter COMT activity (Barbosa et al., 2012a, Desmeules et al., 2014). 
Furthermore, TMD patients display increased mechanical pain coupled with genetic variations that 
alter COMT expression or activity (Smith et al., 2014a). Consistent with these findings, humans 
using COMT inhibitors for the treatment of Parkinson’s disease report heightened visceral and 
generalized pain (Gordin et al., 2004) and animal studies show that inhibition of COMT (Nackley et 
al., 2007, Kambur et al., 2010) produces increased mechanical pain, which we define as COMT-
dependent pain. 
 48 
Despite years of clinical and animal research that focus on the role of sympathetic activity 
and catecholamines in chronic pain conditions, there are few studies that assess specific molecules 
and mechanisms that act downstream from catecholamines and βARs to maintain these chronic pain 
conditions. Previously, we found that the onset of COMT-dependent pain is blocked by antagonists 
for β2- and β3-adrenergic receptors (β2ARs and β3ARs) and their downstream effectors nitric oxide, 
tumor necrosis factor-α (TNFα), interleukin-1β, and interleukin-6 (Nackley et al., 2007, Hartung et 
al., 2014). In this study, we seek to explore if βARs downstream effectors are responsible for the 
maintenance of pain following COMT inhibition. 
It is well established that epinephrine and norepinephrine and cytokine release are tightly 
interwoven. β2ARs are expressed on macrophages, B cells, and T cells (Szelényi and Vizi, 2007). In 
general, activation of βARs on these cells leads to an immunosuppressive effect, decreasing the 
transcription of cytokines (Szelényi and Vizi, 2007, Padro and Sanders, 2014). However, in the 
central nervous system, local epinephrine and norepinephrine has been found to mediate the 
production of pro-inflammatory molecules such as IL-1β (Johnson et al., 2008, Johnson et al., 2013). 
Therefore, catecholamine dyregulation can have a divergent effect in the periphery and in central 
nervous system tissues. Importantly, the release of pro-inflammatory molecules in the central 
nervous system has been associated with increased pain and central sensitization (Marchand et al., 
2005). 
Sustained increases in catecholamines and activation of βARs can lead to activation of the 
MAPK p38, a known molecule that is activated by phosphorylation following a neuropathic or 
inflammatory insult. Stimulation of βARs on microglia (Wang et al., Johnson et al., 2013), 
macrophages (Szelenyi et al., 2006), and astrocytes (Gharami and Das, 2004) can lead to the 
activation of p38.  P38 has been found to be a key modulator of neuropathic and inflammatory pain 
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by activating glia, modulating the transmission of pain signals, and leading to the transcription of 
pro-pain or pro-inflammatory molecules through cAMP response element binding protein (CREB) 
and nuclear factor-κB (NF-κB) activation (Ji et al., 2009). In healthy tissues, glia are relatively 
quiescent, but in the presence of an insult, they can be activated, thereby locally releasing pro-
inflammatory molecules, altering the local environment to encourage synaptic plasticity, and 
upregulating the transcription of pro-pain molecules (McMahon et al., 2005).  
Similar to p38, extracellular regulated kinase 1/2 (ERK1/2) has been found to be activated 
in the dorsal root ganglion and lamina I of the dorsal spinal horn following a variety of painful 
stimuli, including capsaicin (Wei et al., 2006), light touch (Gao and Ji, 2010c), neuropathic pain 
(Obata and Noguchi, 2004, Song et al., 2005), inflammatory pain (Ji et al., 2002), NMDA (Cheng et 
al., 2008) or AMPA receptors (Ji et al., 2009). In addition, ERK1/2 can be phosphorylated via βARs 
in microglia (Wang et al., 2010), macrophages (Tan et al., 2007), astrocytes (Gharami and Das, 2004), 
and Aβ fibers (Khasar et al., 1999b). Activation of ERK1/2 results in upregulation of CREB-
mediated transcription (Song et al., 2005), plasticity, and glial production of pro-inflammatory 
molecules (Ji et al., 2009). Studies have found that microglia express activated ERK1/2 at early time 
points, while astrocytes express activated ERK1/2 at later time points (Zhuang et al., 2007). Thus, 
cell-specific ERK1/2 signaling may be an indicator of pain progression (McMahon et al., 2005, Ji et 
al., 2009). Furthermore, ERK1/2 leads to NF-κB-dependent transcription of genes (Grace et al., 
2014). 
Interestingly, one particular molecule that can activate cells or MAP kinases is TNFα, a pro-
inflammatory cytokine that regulates immune system activation and pro-inflammatory cytokine 
release (Cunha et al., 2005). Previously, we found that circulating levels of TNFα were elevated just 
hours following COMT inhibition (Hartung et al., 2014). TNFα can directly activate nociceptors 
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and increase their firing through its binding to its receptor, TNFR1. TNFα can also increase pain in 
the central nervous system through its ability to activate p38 in astrocytes, microglia (Ji et al., 2009) 
and neurons (Zhang et al., 2010, Gudes et al., 2014). TNFα can more directly act in the spinal cord 
and the dorsal root ganglia (DRG) to elicit pain. In the spinal cord, transplantation of TNFα-
activated astrocytes results in mechanical allodynia (Gao et al., 2010). In DRG, TNFα can increase 
synaptic transmission as well as decrease the activation threshold of neurons. TNFα can also dictate 
pain states by increasing glial activation in the spinal cord and DRG via phosphorylation of p38 or 
ERK1/2 (Ji et al., 2009). For example, bath application of TNFα on peripheral nociceptors results 
in increased nociceptor excitability by altering sodium channel activity via the MAP kinase p38 
(Gudes et al., 2014). Further, TNFα can increase the activation of p38 in microglia or satellite cells 
located in the spinal cord or DRG, and lead to local release of cytokines (Grace et al., 2014) that act 
on local neurons to enhance spontaneous neuronal firing, increase neuronal excitability and reduce 
inhibitory activity (Gao and Ji, 2010b). Conversely, intrathecal TNFα inhibition leads to decreased 
allodynia and reduced spinal p-p38 (Svensson et al., 2003, Svensson et al., 2005). In sum, TNFα may 
represent an important target for patients with fibromyalgia or TMD, particularly because it is 
effective for patients with other chronic pain conditions such as rheumatoid arthritis (Kumar et al., 
2003). 
The MAP kinases p38 and ERK1/2 play key roles in a variety of pain models. For example, 
in neuropathic pain models, p-p38 is upregulated in DRG (Jin et al., 2003) neurons and in spinal 
microglia (Tsuda et al., 2004, Zhuang et al., 2007). As a result, p-p38 translocates to the nucleus and 
subsequently triggers the transcription of pro-inflammatory cytokines including TNFα (Kumar et 
al., 2003). When p38 is inhibited in either neuropathic or inflammatory pain, this treatment reduces 
cytokine production and microglial marker expression.(McMahon et al., 2005) Another MAP kinase, 
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ERK1/2, is required for sensitization. In sum, downstream activation of either neuronal p38 or 
ERK1/2 can contribute to nociceptor sensitization (Xiachun et al., 2006, Gudes et al., 2014). Thus, 
both p38 and ERK1/2 activation, either by TNFα or independent of TNFα, could play important 
roles in altering pain behaviors and cellular (glial or neuronal) activation.  
Taken together, we sought to understand if pain resulting from COMT inhibition would 
require β2- and β3-ARs and/or pro-pain molecules including cytokines as well as the MAPKs p38 
and ERK1/2. We find that the mechanisms required for the onset and maintenance of pain are 
distinct: while β2- and β3ARs are required for the onset of pain resulting from catecholamine 
dysregulation, systemic blockade of β2- and β3ARs does not reverse COMT-dependent pain. 
Furthermore, COMT inhibition results in increased levels of TNFα, p38, and ERK1/2 in the central 
and peripheral nervous system and intrathecal inhibition of either p38 or ERK1/2 reverses COMT-
dependent pain.  
2. Methods 
2.1 Animals  
A total of 138 male Sprague Dawley rats initially weighing between 200-350 g were used. 
2.2 General Experimental Conditions 
For β2- and β3AR antagonism experiments, all animals underwent surgery to receive two 
osmotic mini-pumps (Alzet): one pump to subcutaneously deliver the COMT inhibitor OR486 or 
vehicle (5:3:2, DMSO: Ethanol: 0.9% Saline) and another pump to subcutaneously deliver a cocktail 
containing the β2AR-specific antagonist ICI118,551 (15 mg/kg/day) and the β3AR-specific 
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antagonist SR59230A (1.5 mg/kg/day) or vehicle (4:1, 0.9% Saline: DMSO). Dosages were chosen 
based on the efficacy of dosages outlined in Ciszek et al., 2016. 
For p38 and ERK inhibitor experiments, all animals underwent surgery to receive two 
osmotic mini-pumps (Alzet): one pump to subcutaneously deliver the COMT inhibitor OR486 or 
vehicle beginning on day 0 and the other pump to intrathecally (i.t.) deliver the p38 inhibitor 
SB203580 (12 µg/day), the ERK1/2 inhibitor U0126 (12 µg/day) or vehicle (1:1, DMSO: 0.9% 
Saline) beginning after behavioral testing on day 14. 
2.3 Surgical Procedures 
For all surgeries, animals were anesthetized using isofluorane (5% induction, 1.5-5% 
maintenance).  The incision sites were shaved, disinfected with ethanol and betadine, and sterile 
surgical technique was implemented for all surgical procedures. Wound clips were used to close 
incisions. 
 To deliver peripherally-administered drugs, a pump containing OR486 and either a pump 
with ICI118,551 and SR59230A beginning on day 0 a pump with PE-50 catheter to delay delivery of 
ICI118,551 and SR59230A beginning on day 7, a 2-2.5 cm incision was made between the shoulder 
blades and hemostats were used to make a small pocket to place the Alzet pumps. 
 To delay delivery of ICI118,551 and SR59230A until day 7, we used the Lynch method 
(Lynch et al., 1980), in which we placed coiled polyethylene tubing (PE-50) onto the stainless steel 
flow moderator, which delayed drug delivery according to the length and volume of the tubing.  
 To deliver intrathecally-administered drugs SB203580 or U0126, we used the same method 
as was used in Ciszek et. al, 2016. Here, polyurethane rat intrathecal short catheters  (Durect 
Corporation, Cupertino, CA) were cut on the distal end to 12.5 cm to reach the approximate site of 
 53 
the lumbar spinal cord. Six animals did not awaken after surgeries and these animals were replaced in 
subsequent groups. 
2.4 Assessment of Mechanical Allodynia and Mechanical Hyperalgesia. 
Paw withdrawal threshold was measured using the von Frey up-down method, as described 
in Nackley et al., 2007. Nine calibrated von Frey monofilaments (bending forces of 0.40, 0.68, 1.1, 
2.1, 3.4, 5.7, 8.4, 13.2, and 25.0 g; Stoelting, Wood Dale, IL) with equal logarithmic spacing between 
filaments were applied to the plantar surface of the hind paw. A series of 6 applications of 
monofilaments with varying gram forces was applied for 3 seconds to the plantar surface of the 
hindpaw. Testing began with the middle filament in the series (3.4 g). If the response included the 
withdrawal of the hindpaw, an incrementally lower filament was applied. In the absence of a paw 
withdrawal, an incrementally higher filament was applied. These data were entered into Paw Flick 
module within the National Instruments LabVIEW 2.0 (Austin, TX) software. A logarithmic 
algorithm accounted for the order and number of withdrawal responses as well as the gram force of 
the final filament to calculate mechanical threshold, the gram force that would elicit paw withdrawal 
in 50% of trials (10[Xf+kd]/10,000, where Xf = value [in log units] of the final von Frey hair used; k 
= tabular value of positive and negative responses, and d = mean difference [in log units] between 
stimuli). Mechanical allodynia was defined as a heightened response to a normally innocuous 
stimulus and was determined as a significant decrease in paw withdrawal threshold from baseline.  
After determining paw withdrawal threshold, paw withdrawal frequency to a noxious von 
Frey monofilament was assessed. The highest gram force filament (25.0 g) was applied to the hind 
paw 10 times. Stimulus was applied for 1 second followed by a 1-second interval without a stimulus. 
The number of paw withdrawals was recorded for each hindpaw. Mechanical hyperalgesia was 
defined as an increase in the number of paw withdrawals to a noxious mechanical stimulus from 
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baseline. 
We assessed baseline mechanical sensitivity on day 0. Following surgery, mechanical 
sensitivity was reassessed on days 1, 3, 7, 14, 21, 28 and 35. In all behavioral experiments, the 
experimenter was blinded to treatment.  
2.5 Collection of CSF and blood plasma for cytokine analysis 
After behavioral testing, animals were euthanized by injection of 1.0 - 1.5 mL Fatal-Plus 
(Vortech Pharmaceuticals, Dearborn, MI). For plasma collection, arterial blood was collected and 
placed in EDTA plasma tubes, then centrifuged for 10 minutes at 15,000 g. For cerebrospinal fluid 
collection, fluid was collected from the cisterna magna. After collection, plasma and CSF were flash 
frozen and stored at -80˚C.  
2.6 Collection of tissues for Western Blotting 
Brain regions (including locus coruleus, periaqueductal gray, nucleus accumbens, 
hypothalamus, thalamus, and somatosensory cortex), DRG, spinal were collected from animals on 
day 14 during COMT inhibitor administration and on days 21 and 35 after COMT inhibition. First, 
we assessed differences in cellular activation, including neurons, glial cells, and MAPKs using 
Western blotting to serve as a screen to inform IHC experiments. Time points, structures and 
protein markers with the most significant alterations in cellular activation and/or MAPK activation 
were assessed with IHC. Collected DRG and spinal cord were flash frozen and stored until further 
use. Tissue samples were homogenized in a Precellys tissue homogenizer with tissue protein 
extraction reagent (TPER, ThermoFisher, Carlsbad, CA) and Halt protease and phosphatase 
inhibitor (ThermoFisher, Carlsbad, CA).  
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2.7 Western Blotting 
To accommodate for variation in tissue homogenates, protein concentrations were 
normalized following BCA measurement of protein content to evenly load protein into wells of 
SDS-PAGE gels. Gels were using standard SDS-PAGE methods and transferred onto PVDF 
membrane (Life Technologies, Carlsbad, CA). Membranes were then be blocked, probed with 
primary antibody, and subsequently probed with a corresponding secondary antibody. Following 
addition of ECL Prime (GE Biosciences, Marlborough, MA), blots were be developed using 
chemiluminescence on a GE ImageQuant and assessed for intensity of target signal relative to a 
loading control, βactin. To assess cellular activation, blots were be probed for expression of the 
cellular markers Iba1 (Wako, 1:1000), GFAP (Cell Signaling, 1:300), p-ERK1/2 (Cell Signaling, 
1:1000) and p-p38 (Cell Signaling, 1:500) primary antibodies.  
2.8 Collection of tissues for immunohistochemistry 
Rats were deeply anesthetized with Fatal Plus (Vortech Pharmaceuticals, Dearborn, MI) and 
when no longer responsive to paw- or tail-pinch, they were perfused with 4% paraformaldehyde 
(PFA) in 0.1 M PBS, collected DRG and spinal cord were placed in 4% PFA postfixative overnight. 
Spinal cord and DRG were cryoprotected in 30% sucrose in 0.01M PBS. Tissues were then 
embedded in Optimal Cutting Temperature (OCT) cryomatrix and sectioned by cryostat. Free-
floating spinal cord sections were sliced to 30 µm-thick sections, placed in chilled 0.01M PBS 
containing 0.1% sodium azide, and stored until use. Dorsal root ganglia were sliced to 12 µm-thick 
sections on Superfrost Plus (ThermoFisher, Carlsbad, CA) microscope slides. Slides were dried for 
at least 30 min before storage in -80˚C freezer. 
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2.9 Measurement of cytokines in CSF and blood plasma 
To determine whether COMT inhibition altered cytokine levels in circulating and central 
tissues both during and after COMT inhibition, plasma and CSF were collected at baseline, 14d, 21d 
and 35d for measurement of pro- and anti-inflammatory cytokines. Cytokines levels in plasma and 
CSF were measured by the UNC Cytokine Analysis Facility using the Pro Rat Cytokine 24-plex 
Array (Bio-Plex, Hercules, CA). To confirm results from multiplex, CCL2  levels in plasma were 
measured using the CCL@ Quantikine ELISA Kit (R&D Systems, Minneapolis, MN). All plasma 
and CSF samples were diluted at 2x. 
2.10 Immunohistochemistry 
A combination of antibodies was used to determine p-MAP kinase expression in microglia, 
astrocytes and neurons in spinal cord as well as satellite cells and neurons in dorsal root ganglia. For 
spinal cord staining, anti-p-p38 (1:500, Cell Signaling Cat. No. 9211) or anti-p-p42/44 (1:300, Cell 
Signaling Cat No. 9101, Danvers, MA) in combination with either anti-CD11b (1:500, AbD 
Serotec), anti-S100 (1:500, Abcam), or anti-NeuN (1:500, Millipore, Billerica, MA) were used. For 
DRG staining, the Molecular Probes Neurotrace 530/615 Red Fluorescent Nissl Stain (1:300, 
Molecular Probes, Eugene, OR) was used to stain neuron cell bodies. Secondary antibodies were 
either anti-rabbit or anti-mouse FITC or Alexa Fluor 594 (Jackson Immuno, West Grove, PA). 
Stained tissues were mounted with Vectashield (Vector Laboratories, Burlingame, CA). Images were 
collected on an Olympus IX51 widefield fluorescent microscope. Quantification of 
immunofluorescence for spinal cord was conducted using the Fluorescent Intensity Function 
available on Olympus CellSens software. Quantification of immunopositive cells for dorsal root 
ganglia was performed manually. 
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2.11 Statistical Analysis 
Group differences in behavior were analyzed by two-way ANOVA and corrected for 
repeated measures. Post hoc comparisons were made using the Bonferroni test. P< 0.05 were 
considered significant. For i.t. experiments, behavior was analyzed by performing a two-way 
ANOVA on days 0-14 and days 21-35. Differences in mechanical allodynia or hyperalgesia were 
analyzed by averaging data from days 21-35, performing a one-way ANOVA, and correcting for 
repeated measures. Post hoc comparisons were made with the Holm-Sidak test. For multiplex 
cytokine experiments, data was analyzed for each cytokine using a one-way anova and treatment 
differences over all time points were analyzed. For immunohistochemistry experiments, following 
image acquisition, protein expression was measured by relative fluorescence or by cell counting. Cell 
counters were blinded to treatment. Group differences in p-p38 protein expression were analyzed by 
one-way ANOVA and corrected for repeated measures. Post hoc comparisons were made using the 
Bonferroni test. P<0.05 were considered significant. Group differences in pERK1/2 protein 
expression were analyzed by t-test.  
3. Results  
3.1 β2- and β3AR antagonism prevents the onset of COMT-dependent pain 
 To confirm previous experiments from our lab demonstrating that sustained COMT 
inhibition results in increased mechanical pain, we administered OR486 for 14d by implantation of a 
subcutaneous Alzet mini-pump. As sustained COMT inhibition resulted in increased mechanical 
sensitivity while the COMT inhibitor OR486 was on board and 7-21d after OR486 administration 
had ceased. As expected, we found that sustained OR486 resulted in mechanical allodynia 
(F1,128=199.7, P<0.0001) and mechanical hyperalgesia (F1,128=415.7, P<0.0001) beginning on day 1 
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and lasted while OR486 was on board. Notably, we also found that mechanical allodynia and 
mechanical hyperalgesia lasted for up to 21d following the cessation of OR486 administration. 
We then sought to determine if β2- and β3ARs were required for the initiation of COMT-
dependent pain. Previously, we found that co-administration of the β2AR antagonist ICI118,551 
together with the β3AR antagonist SR59230A was capable of preventing the onset of COMT-
dependent pain. Therefore, here we co-administered two specific pharmacological antagonists 
together with OR486. We found that administration of the β2- and β3AR antagonists together 
prevented the development of OR486-dependent mechanical allodynia (F3,208=64.19, P<0.0001) and 
hyperalgesia (F3,208=194.2, P<0.0001)  beginning on day 1 and lasting through day 35 of the 
behavioral paradigm (Figure 1A,B). 
 
 
 
Figure 3.1. β2- and β3ARS are required for the onset of COMT-dependent pain.  
Animals receiving OR486 for 14d exhibit (A) mechanical allodynia and (B) mechanical hyperalgesia, 
which are blocked by co-administration with ICI118,551 (β2AR antagonist) and SR59230A (β3AR 
antagonist). N=4-8 per group. Data are mean + SEM. ****p<0.0001. 
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3.2 β2- and β3AR antagonism does not reverse COMT-dependent pain 
To next evaluate if β2- and β3ARs were important in the maintenance of COMT dependent 
pain, animals underwent surgery as discussed above. However, here, we wanted to determine if 
delayed delivery of drug would reverse COMT-dependent pain. Therefore, on surgery day, we 
implanted a mini-osmotic pump that delayed delivery of the β2- and β3AR antagonists until day 7. 
We found that blockade of β2- and β3ARs did not reverse COMT-dependent pain. Rather, these 
animals exhibited mechanical hyperalgesia and allodynia similar to that of the animals receiving only 
OR486 (Figure 2A,B). Therefore, β2- and β3ARs are required for the onset, but not the maintenance 
of COMT-dependent pain. 
Figure 3.2. β2- and β3ARS are not required for the maintenance of COMT-dependent pain.  
Animals receiving OR486  for 14d exhibit (A) mechanical allodynia and (B) mechanical 
hyperalgesia, which is not blocked by co-administration with ICI118,551 (β2AR antagonist) and 
SR59230A (β3AR antagonist). N=4-8 per group. Data are mean + SEM. ****p<0.0001. 
3.3 Catecholamine dysregulation results in altered in circulating and central cytokine release 
 Because we found that β2- and β3ARs were not required for the onset of COMT-dependent 
pain, we sought to determine the changes taking place in the periphery and the CNS before, during, 
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and after sustained OR486 administration. Previously, we found that intraperitoneal administration 
of OR486 led to increases in pro-inflammatory molecules (TNFα, IL-1β, IL-6, and CCL2) 4h after 
OR486 administration (Hartung et al., 2014). We collected blood plasma and CSF from animals at 
baseline, 14d, 21d and 35d and measured circulating and central cytokines using a cytokine multiplex 
that measures pro- and anti-inflammatory cytokines.  
In blood plasma, we did detect significant group differences between animals receiving 
vehicle compared to those receiving OR486. However, while we did not observe individual 
differences in cytokines, there was a noticeable trend towards universal decreases in both pro-and 
anti-inflammatory cytokines in animals receiving OR486 compared to controls (Figure 3A-X).  
 
 
Figure 3.3. Sustained COMT inhibition results in decreases in pro- and anti-inflammatory cytokines.  
Animals receiving OR486 for 14d exhibited lower levels of cytokines in blood plasma. N=4-6 per 
group. Data are expressed as mean + SEM.  
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In CSF, we did find that there were increases in some pro-inflammatory markers. While 
there were trends towards a pro-inflammatory state in the CSF (Figure 4A-N), we observed group 
differences in CSF levels in TNFα that trended toward significance (p<0.076, Figure 5).  
 
Figure 3.4. Sustained COMT inhibition results in no differences in pro- and anti-inflammatory 
cytokines in cerebrospinal fluid.  
Animals receiving OR486 for 14d exhibited lower levels of cytokines in blood plasma. N=3 per 
group. Data are expressed as mean + SEM. 
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Figure 3.5. Sustained COMT inhibition results in elevated levels of central TNFα.  
Animals receiving OR486 for 14d exhibited elevated levels of TNFα in cerebrospinal fluid. Inset is 
average of baseline or TNFα concentration over days 14-35.  Group differences between groups 
were P= 0.076. N=3 per group. Data are expressed as mean + SEM. 
3.4 Catecholamine dysregulation results in elevated levels of p-p38 and p-ERK1/2 
 Because of their implications with pain and βAR activation, we sought to understand if MAP 
kinases were altered in animals receiving OR486 in both dorsal root ganglia and the dorsal horn of 
the spinal cord. We found that COMT inhibition resulted in a significant increase in p-p38 in the 
dorsal spinal horn on days 14, 21 and 35 (Figure 6A-I). We observed significant differences in the 
relative fluorescence of p-p38 in lamina I/II on days 14 and 21 (Figure 6G,H). P-p38 co-localized 
with neurons and astrocytes in spinal dorsal horn (Figure 6J-L). 
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Figure 3.6. P-p38 levels are elevated in dorsal spinal horn.  
Animal receiving OR486 exhibited elevated levels of activated, phospho-p38 in the spinal dorsal 
horn on (A-I) Days 14-35.  N=3-4 per group.  P-p38 is expressed in (J-L) neurons and astrocytes, 
but not microglia, in the dorsal horn.  Scale bar = 100 µm. Data are expressed as mean + SEM. 
*p<0.05 
 
While we found differences in p-p38 in the dorsal spinal horn, we did not observe 
differences in levels of ERK1/2 in the dorsal spinal horn. However, we did see increased that there 
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were observable increases in the number of cells expression p-ERK1/2 in nociceptors in the dorsal 
root ganglia at day 14 (Figure 7).  
 
Figure 3.7. Phospho-ERK1/2 levels are elevated in dorsal root ganglion on Day 14.  
Animal receiving OR486 exhibited (G) elevated, albeit not significant, levels of activated, p-ERK in 
dorsal root ganglia. Scale bar = 50 µm. N=3-4 per group. Data are expressed as mean + SEM. 
P=0.067 
 
We report changes in p-p38 and ERK1/2 in the spinal cord and DRG respectively, but we 
also assessed expression of the phosphorylated versions of these molecules in supraspinal sites. 
Using a combination of Western blotting and immunohistochemistry, we measured expression of 
phosphorylated p38 and ERK1/2 as well as the markers for astrocyte (GFAP), and microglial (Iba1) 
activation (Supplemental Figure 1). We did not detect significant differences in phosphorylated 
MAPKs nor in cellular activation. These data suggest that the most dynamic changes were occurring 
not in the brain, but rather in spinal cord and DRG. 
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3.5 Blockade of p38 or ERK1/2 reverses COMT-dependent pain 
 Because we observed that OR486 administration resulted in elevated levels of activated p38 
and ERK1/2 in the spinal cord and DRG, we then sought to determine their role in the 
maintenance of COMT-dependent pain. To first evaluate the role of spinal p38 in COMT-
dependent pain, we implanted an osmotic mini-pump to intrathecally deliver the p38 inhibitor 
SB203580 or vehicle on day 14.5 (after measuring mechanical pain). As expected, animals receiving 
OR486 developed mechanical allodynia (F3,105=13.43, P<0.0001)   and hyperalgesia (F3,102=13.35, 
P<0.0001.  Administration of SB203580 reversed both mechanical allodynia (F3,63=16.96, P<0.0001) 
and hyperalgesia (F3,63=16.89, P<0.0001). Therefore, p38 is required for the maintenance of COMT-
dependent pain (Figure 8A,B). 
 We then sought to determine if ERK1/2 played a role in the maintenance of COMT-
dependent pain. We measured pain behavior in animals receiving OR486 for 14d and performed 
surgery to deliver an intrathecal dose of either the ERK1/2 inhibitor U0126 or vehicle. Animals 
receiving OR486 developed mechanical allodynia (F3,90=9.707, P<0.0001) and hyperalgesia 
(F3,88=12.97, P<0.0001). Results show that ERK1/2 inhibition reversed mechanical allodynia 
(F3,54=15.05, P<0.0001), but did not reverse mechanical hyperalgesia (Figure 8C,D).  
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Figure 3.8. p38 and ERK1/2 contribute to the maintenance of COMT-dependent pain.  
Animals receiving OR486  for 14d exhibit (A) mechanical allodynia and (B) mechanical 
hyperalgesia, which is reversed by intrathecal administration of SB203580 (p38 inhibitor). 
Administration of intrathecal U0126 (ERK1/2 inhibitor) reversed (C) mechanical allodynia but 
not (D) mechanical hyperalgesia. Insets are average of days 21-35. N=6-8 per group. Data are 
mean + SEM. *p<0.05, **p<0.01,***p<0.001 vs. Vehicle/OR486.  
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4. Discussion 
4.1 β2- and β3ARs are required for the onset, but not the maintenance, of COMT-dependent pain 
 Previously, our group found that blockade of β2- and β3ARs was capable of preventing the 
onset of COMT-dependent pain that lasted less than 4.5h (Hartung et al., 2014). Since then, we have 
found that the onset of sustained COMT inhibition results in pain through peripheral, but not spinal 
or supraspinal, β2- and β3ARs (Ciszek et al., 2016). These data are important because they suggest a 
peripheral site of action for the onset of COMT-dependent pain. Together with data demonstrating 
that β2- and β3AR antagonism does not reverse COMT-dependent pain, these findings suggest that 
peripheral βARs are important for the onset of COMT-dependent pain, but they do not contribute 
to the maintenance of COMT-dependent pain. 
 One way in which β2- and/or β3ARs may drive the onset, but not the maintenance, of pain is 
through changes in the second messenger cascade associated with βAR activation. In a report by 
Khasar and colleagues, researchers found that epinephrine-induced hyperalgesia led to a priming 
event such that subsequent administration of epinephrine resulted in βARs decoupling from the 
canonical Gs downstream pathway and switching to Gi/o. This switch caused an increase in the firing 
of IB4+ nociceptors as well as a shift from PKA and PKC second messenger pathways to ERK1/2 
activation (Khasar et al., 1999b). Because we too observed modest increases in ERK1/2 in DRG, 
this may be the means by which βAR activation no longer plays a decreased role in pain. Another 
way in which βAR may play a lesser role is through action by β-arrestin, which can bind to βARs to 
either desensitize or internalize the receptor (DeWire et al., 2007). β-arrestin binds to βARs that are 
phosphorylated by the βAR kinase known as G-protein receptor kinase 2 (GRK2)(Krasel et al., 
2005). Furthermore, GRK2 is involved in the switch intracellular pathways within sensory neurons 
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to prolong epinephrine-induced pain (Wang et al., 2011). Therefore, GRK2 and β-arrestin may play 
an important role in βAR desensitization and/or intracellular signaling during the transition from 
the onset to the maintenance of COMT-dependent pain.  
4.2 p38 and ERK1/2 involvement in maintenance of COMT-dependent pain  
Because of their close links to βAR signaling and chronic pain states, we next sought to 
understand what molecules may be important for the maintenance of pain. We chose to study 
MAPKs for two main reasons: (i) their activation is considered to be a correlate of elevated 
nociception in various pain models and (ii) they are activated by pro-inflammatory molecules (Ji et 
al., 2009). We found that p-p38 levels were elevated primarily in neurons, but also in astrocytes, 
following 14d of COMT-dependent pain. Furthermore, we saw that these changes were significantly 
different through day 21. Together with our data demonstrating that p38 inhibition reverses COMT-
dependent pain, these data point to persistent activation of p38 as a key contributor to COMT-
dependent pain.  
While previous reports for neuropathic and inflammatory pain find that p-p38 co-expresses 
with microglia (Boyle et al., 2006, Ji and Suter, 2007), here we found that p-p38 was expressed in 
neurons and astrocytes. One way in which p-p38 may act in spinal neurons is through its ability to 
trigger inhibitory synaptic transmission of GABAergic interneurons in the spinal cord. Furthermore, 
researchers found that p38 is activated downstream of TNFα and its receptor tumor necrosis factor 
receptor 1 (TNFR1)(Zhang et al., 2010). While our data does not directly assess which type of 
neurons co-express p-p38, many of the p-p38-positive neurons were located in lamina I/II, where a 
number of glutamic acid decarboxylase 65 (GAD65) GABAergic interneurons are located (Lorenzo 
et al., 2014). Similar to results in neurons, p-p38 activation in astrocytes can be driven through 
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TNFR1 activation, leading to the transcription of inducible nitric oxide synthase (iNOS) in vitro (Da 
Silva et al., 1997). Given that we observed elevated levels of central TNFα throughout the paradigm, 
this may be one possible mechanism by which p-p38 is activated via TNFR1 residing on neurons 
and astrocytes located in the dorsal spinal horn. 
We also observed that there were elevated levels of ERK1/2 in the dorsal root ganglion, but 
not in the spinal cord. One reason why ERK1/2 may not be activated in the spinal cord is because 
observable differences in ERK1/2 in the spinal cord are generally limited to high-frequency stimuli 
that activate Aδ-fibers. Our data are in line with those of Khasar and colleagues, who found that 
epinephrine treated nociceptors led to elevated levels of ERK1/2 downstream of the β2AR-Gi/o 
pathway. This pathway represents one of three possible pathways that could be activated: the other 
two being the PKC and PKA pathways (Khasar et al., 1999b). While we did not distinguish between 
ERK1 and ERK2 here, researchers have found that ERK2 may play a more central role in 
mechanical sensitization, particularly as a result of inflammatory pain (Alter et al., 2010, O'Brien et 
al., 2015). Active ERK1/2 may lead to a number of different effects, including phosphorylation of 
the NR1 subunit of NMDA receptors as well as induction of the transcription factor cAMP-
response element binding protein, which is important for up regulation of genes involved in long-
term potentiation as well as other pro-pain genes like Cox2, TrkB, and BDNF (Ji et al., 2009).  
4.3 Catecholamine dysregulation and pain 
 Our data also show that there is a general trend towards decreased cytokine levels in blood 
plasma and increased cytokine levels in CSF. Clinically, it is well established that elevated levels of 
norepinephrine may play a role in the pathology of immune mediated diseases (Cohen et al., 2007). 
In particular, sustained norepinephrine elevations have been linked to immunosuppression in 
peripheral tissues and immune cells (Padro and Sanders, 2014). βARs are expressed on a variety of 
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different immune cells including macrophages, lymphocytes and mast cells (Szelenyi et al., 2006). 
Research indicates that while βAR stimulation in already activated immune cells (e.g. by LPS or a 
pathogen) may decrease the production of cytokines, AR stimulation on quiescent immune cells may 
result in the production of cytokines (Szelenyi et al., 2006, Szelényi and Vizi, 2007). Experimental 
data support this hypothesis: increased activity of the sympathetic nervous system results in 
decreased release of Th1-type cytokines (e.g. TNFα, IL-1β, IL-6). This downregulation in cytokine 
release may be a result of a macrophage specific Gs- to Gi switch, as Magocsi and colleagues found 
that TNFα levels were elevated in cultured macrophages following βAR stimulation via Gi-protein 
coupling to macrophage specific βARs (Magocsi et al., 2007). These data may describe why we 
observed universal decreases in circulating cytokines throughout our paradigm. 
  At present, there is not a consensus on whether circulating pro- or anti-inflammatory 
cytokine levels are altered in patients with chronic pain disorders. In a study conducted in female 
patients with fibromyalgia, researchers found that macrophage release of pro-inflammatory 
cytokines IL-1β, TNFα, IL-6, IL-10, IL-8, IL-18, MCP-1 was higher compared to healthy controls 
(Bote et al., 2012). Given that our study looked only at whole blood, not at the individual cell level, it 
is possible that we were not able to detect these more subtle, cell-specific changes in cytokine 
release, particularly in macrophages. However, it is also possible that NE release has an opposite 
effect on myeloid- and lymphoid-derived cells (Szelényi and Vizi, 2007). In addition, due to the 
circadian nature of the release of both norepinephrine/epinephrine and cytokines (Padro and 
Sanders, 2014), it may be more difficult to correlate circulating levels of these molecules in a clinical 
study. 
In a study that assessed levels of cytokines from patients with fibromyalgia, Kosek and 
colleagues found that levels of the cytokines IL-4 , IL-8 IL-10 were upregulated in the CSF of 
fibromyalgia patients compared to healthy controls (Kadetoff et al., 2012, Kosek et al., 2015), similar 
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to results from our data. These data support more basic science studies that have found that βAR 
activation in the central nervous system can result in neuroinflammation (Johnson et al., 2008).  
Given that the sympathetic nervous system may be involved in these chronic pain conditions and 
that central βAR activation increases production of inflammatory cytokines, assessing cytokine levels 
in the CSF may be an informative measure to assess disease progression in pain patients.  
4.4 Onset and maintenance: a changing site of action 
 Previously, our group found that COMT-dependent pain was primarily driven by 
mechanisms in the peripheral nervous system. Of note, blockade of either β2- and β3ARs or pro-
inflammatory molecules in the periphery was able to prevent the onset of acute (<4.5h) COMT-
dependent pain (Hartung et al., 2014). Furthermore, blockade of β2- and β3ARs at the onset of 
sustained COMT-dependent pain prevented the development of mechanical and thermal pain 
(Ciszek et al., 2016). Here, though, we find that COMT-dependent pain outlasts its initiating 
stimulus, COMT inhibition, by some three weeks and is not maintained by β2- and β3ARs. We also 
see that these animals do not have heightened inflammation in the periphery. Taken these lines of 
evidence together, it is clear that the maintenance of COMT-dependent pain is not driven by 
peripheral mechanisms. Rather, our findings suggest that COMT-dependent pain is maintained by a 
central mechanism. This evidence includes the upregulation of cytokines in CSF, together with 
increased p-p38 expression in spinal neurons and astrocytes, increased pERK1/2 in sensory neuron 
cell bodies in DRG, and the ability for spinally delivered p38 or ERK1/2 inhibitors to reverse 
mechanical hyperalgesia and/or allodynia. 
 Indeed, it is well known that recurring high-frequency stimulation of nociceptors results in a 
pain-facilitory state in which central synapses are altered at the neuronal and biochemical level to 
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thereby heighten pain transmission (Grace et al., 2014). While we did not directly measure activation 
of nociceptor activity, we do see that in the absence of a known stimulus (e.g. COMT inhibitor), 
animals that received 14d of the COMT inhibitor continued to exhibit mechanical allodynia and 
hyperalgesia for weeks following the cessation of the drug. Furthermore, p-p38 has been attributed 
to be activated in the spinal dorsal horn of rodents with that have elevated activation of spinal nerve 
ligation (Jin et al., 2003), intraplantar CFA (Boyle et al., 2006), and peripheral nerve injury (Tsuda et 
al., 2004). Therefore, heightened nociceptive activity may have resulted in this pain facilitory 
response of p38 activation.   
4.5 Clinical implications and greater observations 
 Here, we observed that sustained COMT inhibition results in increased pain through 
activation of peripherally located β2- and β3ARs during the onset phase and centrally-located 
MAPKs during the maintenance phase. While βAR antagonists have been used for some chronic 
pain conditions such as TMD and migraine, they are only effective for a subset of patients or require 
patients to take a beta-blocker as a preventative measure against future pain, and only reduce the 
frequency of migraine, but do not relieve their intensity or prevent them completely (Silberstein et 
al., 2012). However, there is limited evidence that βAR-antagonism acts as an effective treatment for 
patients with fibromyalgia, as most studies are conducted with small sizes (Light et al., 2009b) or 
without the use of a placebo in the study (Wood et al., 2005). Therefore, novel therapeutics that 
incorporate effectors downstream catecholamine dysregulation may be more successful at relieving 
pain experienced by chronic pain patients. However, it may also be important to assess some of the 
compensatory mechanisms that may occur as a result of decreased COMT activation, such as 
decreased release of catecholamines in the central nervous system. This, counterintuitively, may be 
why drugs such as duloxetine, a dual reuptake inhibitor that increases levels of serotonin and 
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norepinephrine in the central nervous system is efficacious for patients with fibromyalgia (Arnold et 
al., 2004): observed increases in pain following COMT inhibition may result in decreased release of 
norepinephrine in the central nervous system, thereby attenuating the effects of descending 
inhibition by αARs. Therefore, future studies will look at the role of descending inputs on the 
facilitation of pain in our model. 
 At present, there are few studies that have assessed the efficacy of p38 inhibitors in 
populations of patients with idiopathic pain conditions such as TMD and fibromyalgia. However, 
there are a number of promising Phase II trials for patients with osteoarthritis or neuropathic pain 
(Hayes et al., 2014). As drug development for these p38 inhibitors continues, our data suggest that 
future work should incorporate patient populations with one or more idiopathic pain condition. 
Given that there is a direct link between TNFα and p38 activation in basic science data, use of 
TNFα inhibitors may also be an alternative mechanism to treating patients with fibromyalgia. As 
such, use of a spinally-delivered inhibitor of TNFα activity, etanercept, has been found effective in 
patients with fibromyalgia (Tobinick, 2010). Taken together, these data suggest that while βAR 
antagonists may be more effective for patients that have recently developed idiopathic pain 
disorders, while drugs that target specific downstream effectors such as p38 or TNFα in the CNS 
may be more effective for those patients with more advanced stages (e.g. were diagnosed earlier) of 
idiopathic pain. Future studies will assess the role of βARs in the ability to induce changes in p38 
and TNFα activation. 
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Supplemental Figure 3.1 COMT Inhibition does not result in significant differences in cell activation 
in discrete brain regions.  
No differences were detected in locus coeruleus (LC), periaqueductal gray (PAG), thalamus (Thal), 
hypothalamus (Hypo), somatosensory cortex (SS), or nucleus accumbens (NAcc) for astrocyte 
activation (GFAP), microglial activation (Iba1), p-p38, or pERK1/2. Protein expression relative to 
β-actin. Data expressed as mean + SEM.   
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Chapter 4: Nuclear Factor-κB Regulates Pain and COMT Expression 
1. Introduction 
The signaling complex nuclear factor-κB (NF-κB) is a key regulator of molecules and 
pathways important for inflammation and pain. NF-κB can exist as homo- or heterodimers 
composed of the Rel family proteins including p65, p50, p52, RelB, and c-Rel, with the p65/p50 
heterodimer being the canonical form.(Kaltschmidt and Kaltschmidt, 2009) In its inactive state, NF-
κB is bound in the cytoplasm bound to inhibitors of κB (IκBα). Upon activation by pro-
inflammatory cytokines (e.g., interleukin-1β; IL-1β and tumor necrosis factor α; TNFα), growth 
factors (e.g., epidermal growth factor; EGF) (Kaltschmidt et al., 2005), or adjuvants that stimulate 
toll-like receptors 2 and 4 (e.g., complete Freund’s adjuvant; CFA)(Lee et al., 2004), the IκB kinase 
(IKK) phosphorylates IκBα, tagging it for degradation. As a result, IκBα releases the p65/p50 
complex, which subsequently translocates to the nucleus and initiates transcription of κB-associated 
inflammatory genes such as TNFα, IL-1β, and cyclooxogenase-2 (COX-2) that directly or indirectly 
influence pain.(Scholz and Woolf, 2002, Kaltschmidt and Kaltschmidt, 2009). 
Activation of NF-κB in humans is implicated in a variety of pain conditions such as 
rheumatoid arthritis, migraine, and nerve injury (Niederberger and Geisslinger, 2008). In patients 
with rheumatoid arthritis, NF-κB-linked proteins are upregulated in synovial tissues (Marok et al., 
1996). In addition, patients that experience chronic migraines express increased IκBα in blood 
monocytes concurrent with increased migraine intensity (Sarchielli et al., 2006b). Accordingly, NF-
κB is upregulated in the dorsal root ganglia and spinal cord of animals experiencing inflammatory 
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and neuropathic pain (Ma and Bisby, 1998, Ledeboer et al., 2005, Wu et al., 2006, Lee et al., 2011). 
Inflammation-evoked pain is attenuated by knockdown of p50 (Niederberger et al., 2007), gene 
silencing of p65 (Luo et al., 2014), or by administration of a proteasome inhibitor that prevents 
IκBα dissociation from p50 and p65 (Ahmed et al., 2014). Similarly, pain following nerve injury is 
reversed by administration of an NF-κB decoy that prevents activated NF-κB from binding to a 
consensus DNA fragment and initiating transcription (Sakaue et al., 2001, Inoue et al., 2006).  
While NF-κB is ubiquitously expressed in a variety of cell types,(Lawrence, 2009) its 
contribution to pain is driven in large part by its signaling in astrocytes. Astrocytes are glial cells 
located in the central nervous system that participate in the transmission of neuronal signaling and 
provide neuroprotection during synaptic remodeling or neurodegeneration (Kaltschmidt et al., 
2005). In animal studies, astrocytic NF-κB is upregulated following viral coat protein-induced 
inflammation (e.g. gp120) (Ledeboer et al., 2005), CFA-induced inflammation (Ledeboer et al., 2005, 
Luo et al., 2014), and nerve injury (Lee et al., 2011). Likewise, loss of astrocytic NF-κB signaling 
attenuates pain following formalin administration (Fu et al., 2008) or spinal nerve injury (Ma and 
Bisby, 1998). While these studies point to the contribution of astrocytic NF-κB activity in pain, 
more research is required to identify downstream pain-relevant molecules. 
Recent work by our group suggests that activation of NF-κB in astrocytes may produce pain 
by regulating the expression of catechol-o-methyltransferase (COMT), an enzyme that inactivates 
catecholamines and modulates pain (Tchivileva et al., 2009a). Specifically, we found in vitro evidence 
demonstrating that TNFα-induced activation of NF-κB in a human astrocyte (H4) cell line led to 
binding of p65 to the P2 promoter region of the Comt gene, thereby reducing COMT mRNA and 
protein expression. Reduced COMT expression and activity is associated with heightened pain 
sensitivity in patients with chronic pain conditions (Diatchenko et al., 2005, Smith et al., 2014b). 
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Furthermore, pharmacological inhibition of COMT increases pain in animals (Nackley et al., 2007, 
Hartung et al., 2014). Therefore, COMT may represent a novel molecular target for NF-κB that 
dictates pain behaviors. 
Building on in vitro work demonstrating that NF-κB downregulates COMT expression 
together with in vivo work demonstrating the role of COMT in pain, the purpose of the present study 
was to examine the relationship between systemic and astrocyte-specific NF-κB activity, pain, and 
COMT expression in an animal model of inflammation. Specifically, we evaluated the effects of NF-
κB inhibition in rats or overexpression in mice on pain behavior and COMT expression following 
local administration of CFA. We hypothesized that induction of NF-κB by the pro-inflammatory 
stimulant CFA would result in enhanced pain and decreased COMT protein expression.  
2. Materials and Methods 
2.1 Animals 
Seventy-eight adult male Sprague-Dawley rats (250-320g; Charles River Laboratories, 
Raleigh, NC) were used in behavior and molecular experiments. Eighty-eight male C57Bl6 
expressing constitutively active form of IκB kinase (IKK) in GFAP+ cells (IKK constitutive 
activity, hence “IKKca”) and littermate control (Co) mice (25-35 g; a gift from the lab of Dr. Ken 
McCarthy) were used in behavior and molecular experiments. All procedures were approved by the 
University of North Carolina Animal Care and Use Committee and adhered to the guidelines of the 
Committee for Research and Ethical Issues of the IASP (Zimmermann). 
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2.2 General Experimental Methods 
To evaluate the role of NF-κB in regulating inflammatory pain and COMT expression in 
rats, separate groups received an intraperitoneal (i.p.) injection of the NF-κB inhibitor MG132 (10 
mg/kg) or vehicle (10% DMSO in 0.9% saline) one hour prior to a unilateral intraplantar (i.pl.) 
injection of CFA (200 µl) or saline (200 µL). In mice, separate groups of IKKca or Co mice received 
a unilateral i.pl. injection of CFA (20 µL) or incomplete Freund’s adjuvant (IFA; 20 µL). IFA is 
identical in its chemical composition to CFA, but does not contain Mycobacterium tuberculosis, which is 
responsible for the induction of inflammation. Behavioral responses to mechanical and thermal 
stimuli were reassessed at acute (1h, 6h, 1d), subchronic (3d, 5d, 7d), and chronic (9d, 11d, and 13d) 
phases of inflammation, as outlined by Raghavendra et al., 2004 (Raghavendra et al., 2004). In all 
studies, the experimenter was blinded to the experimental conditions.  
2.3 Assessment of Mechanical and Thermal Pain Sensitivity  
Rats and mice were handled and habituated to the testing environment for 4d prior to 
establishing baseline responsiveness to mechanical and thermal stimuli. First, animals were placed in 
plexiglass cages positioned over an elevated mesh stainless steel platform and habituated to the 
environment for 20 min. Mechanical allodynia and hyperalgesia were assessed using repetitive 
presentation of either an innocuous or noxious stimulus, as used in Ringkamp et al., 1999 and Fecho 
et al., 2005. Mechanical allodynia was assessed by placing a normally innocuous von Frey filament 
(3.632g for rat; 0.166g for mouse) onto the plantar surface of the hindpaw ten times for 1s with an 
inter-stimulus interval of 1s. Mechanical hyperalgesia was assessed by placing a normally noxious 
von Frey filament (15g for rat; 1.494g for mouse) onto the plantar surface of the hindpaw ten times 
for 1s with an inter-stimulus interval of 1s. Mechanical allodynia or hyperalgesia was defined as an 
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increase in the frequency ([number of paw withdrawals/10] x 100%) of paw withdrawals evoked by 
stimulation with the von Frey monofilaments compared to baseline.  
Thermal hyperalgesia was assessed using the Hargreaves method as described 
previously.(Nackley et al., 2007) Briefly, animals were placed on an elevated heated glass platform 
maintained at 30˚C and habituated to the environment for 20 min. A radiant beam of light was 
applied to the plantar surface of the hindpaw and the latency to withdrawal for a maximum of 20s 
was recorded. Withdrawal latency was measured in duplicate for each paw, with an inter-stimulus 
interval of 5 min. If the difference between the duplicate measures was >4s, a third measurement 
was taken. The two most consistent measurements were included in the analysis. Thermal 
hyperalgesia was defined as a decrease in paw withdrawal latency compared to baseline.  
2.4 Assessment of COMT Protein Expression in Nervous System Tissues 
COMT expression was measured in tissues collected from separate groups of rats sacrificed 
at 6h, 1d, or 5d following experimental treatment and from mice sacrificed at 1h, 6h, 1d, 3d, 5d, or 
11d following experimental treatment. The specific tissues collected include the dorsal root ganglia 
(DRG), spinal cord, and brain regions (hindbrain [locus coeruleus and periaqueductal gray], 
midbrain [thalamus and hypothalamus] or forebrain [primary somatosensory cortex and nucleus 
accumbens]).  
Total protein from each discrete tissue region was diluted in tissue protein extraction reagent 
(TPER; Thermo Scientific; Rockford, IL) with protease inhibitor (Pierce; Rockford, IL) and 
homogenized using the Precellys Homogenizer system (MD, USA). Soluble protein concentrations 
were assessed and normalized using a BCA Protein Assay Kit (Pierce; Rockford, IL), run at 10-50 µg 
on precast 12% Tris-Glycine gels (Bio-Rad; Hercules, CA), and transferred onto PVDF membranes 
using the iBlot Dry Blotting system (Invitrogen; Waltham, MA). Following transfer, blots were 
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blocked using 5% w/v bovine serum albumin diluted in TBST for 1h and incubated in either anti-
COMT primary antibody (BD Biosciences; San Diego, CA) diluted at 1:7,500 in blocking buffer 
solution or anti-β-actin primary antibody (Cell Signaling; Danvers, MA) diluted at 1:3,000 at 4˚C 
overnight. Chemiluminescence was detected on a ImageQuant TL system and analyzed using 
ImageQuant TL 3000 software (GE Healthcare; Piscataway, NJ). COMT is expressed as one of two 
isoforms: a membrane-bound isoform (~30 kDa) and soluble isoform (~25 kDa). Densitometry 
volume was analyzed as the sum of both COMT isoforms normalized to β-actin densitometry 
values.  
2.5 Statistical Analysis  
Behavioral data were analyzed by one-way analysis of variance (ANOVA) for repeated 
measures. Post hoc comparisons were performed using the Bonferroni’s test. Normalized protein 
data were analyzed by unpaired t-test with post-hoc tests. P < 0.05 was considered to be statistically 
significant. 
3. Results 
3.1 NF-κB inhibition attenuates inflammation-evoked increases in pain sensitivity in rats 
To evaluate the role of NF-κB in regulating pain sensitivity in the CFA model of 
inflammation, separate groups of rats received i.p. administration of the NF-κB inhibitor MG132 or 
vehicle 1h prior to i.pl. administration of CFA or saline. Behavioral responses to mechanical and 
thermal stimuli were then assessed during acute, subchronic, and chronic phases of inflammation.  
Prior to the induction of inflammation, responsiveness to mechanical and thermal stimuli 
did not differ between groups. Following administration of i.pl. CFA, rats exhibited mechanical 
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allodynia, mechanical hyperalgesia, and thermal hyperalgesia in the ipsilateral paws. CFA-induced 
increases in pain sensitivity were observed 1h following administration and lasted throughout the 13-
day testing period. Administration of MG132 prior to CFA attenuated inflammation-evoked 
mechanical allodynia and thermal hyperalgesia during acute, subchronic, and chronic phases (F9,112 = 
6.06, P < 0.0001; Figure 1A and F9,112 = 6.027, P < 0.0001; Figure 1C, respectively). Pre-emptive 
administration of MG132 also attenuated inflammation-evoked mechanical hyperalgesia during 
subchronic and chronic phases (F9,112 = 13.19, P < 0.0001; Figure 1B). No differences in behavioral 
responsiveness to mechanical and thermal stimuli were observed following MG132 administration in 
the absence of CFA or in the contralateral non-injected paws.   
 
Figure 4.1. Blockade of NF-κB reduces CFA-induced pain in rats.  
Intraplantar administration of CFA (200 µL) increases (A) mechanical allodynia, (B) mechanical 
hyperalgesia, and (C) thermal hyperalgesia. Pretreatment with MG132 (20 mg/kg dosage) attenuated 
mechanical allodynia and hyperalgesia compared to Vehicle/CFA. N=8 per group. Data are mean + 
SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 different from Vehicle + Saline for larger 
graphs and different from MG132+CFA for inset graphs.  
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3.2 Constitutive activity of astrocytic NF-κB prolongs CFA-induced pain in mice  
We next sought to determine if constitutive activity of the astrocytic NF-κB pathway would 
alter inflammatory pain behaviors. Separate groups of IKKca and Co mice received i.pl. CFA or 
IFA. Behavioral responses to mechanical and thermal stimuli were then assessed during acute, 
subchronic and chronic phases of inflammation.  
Compared to their Co littermates, IKKca mice displayed prolonged increases in mechanical 
allodynia (F27,457 = 2.130, P<0.001; Figure 2A) and mechanical hyperalgesia (F27,456 = 3.247, 
P<0.0001; Figure 2B) in the affected ipsilateral paw beginning on day 3, which lasted throughout the 
13-day testing period (Figure 2A-C). Furthermore, while we observed no changes in mechanical or 
thermal pain in the unaffected contralateral paw of Co mice, we did observed increased mechanical 
allodynia and hyperalgesia in the contralateral paw of IKKca mice beginning on day 3, during the 
subchronic phase of inflammatory pain, and lasting until the end of the behavioral paradigm. We did 
not observe significant differences in thermal hyperalgesia in IKKca and Co mice. As expected, no 
differences in pain behaviors were observed between IKKca and Co mice following IFA 
administration for mechanical allodynia (F9,162=0.270, P=0.982), mechanical hyperalgesia 
(F9,162=0.926, P=0.504), or thermal hyperalgesia (F9,178=0.496, P=0.876) (Supplementary Figure 1A-
C).  
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Figure 4.2. Mice expressing constitutively active IKK exhibit enduring pain following CFA 
treatment compared to Co.  
Intraplantar administration of CFA (20 µL) increases (A) mechanical allodynia, (B) mechanical 
hyperalgesia, and (C) thermal hyperalgesia. While CFA-mediated (A) mechanical allodynia and (B) 
mechanical hyperalgesia subside in Co mice, IKKca mice exhibit prolonged mechanical allodynia 
and hyperalgesia compared to Co contra.  No differences were observed in thermal hypersensitivity 
following CFA administration between IKKca and Co mice. N=10-13 per group. Data are mean + 
SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 different from Co/ contra. 
 
3.3 NF-κB inhibition blocks inflammation-evoked reductions in COMT protein expression in rats 
After establishing that NF-κB activity mediated pain behavior in the CFA model of 
inflammation, we sought to assess the role of NF-κB in regulating the expression of COMT. 
Separate groups of rats received an i.p. dose of the NF-κB inhibitor MG132 or vehicle 1h prior to 
i.pl. administration of CFA or saline and were sacrificed at 6h, 1d, and 5d after CFA injection. 
Tissues from forebrain (nucleus accumbens, primary somatosensory cortex) and midbrain (thalamus 
and hypothalamus), hindbrain, and lumbar spinal cord were collected for analysis of COMT protein 
levels. CFA administration produced noticeable reductions in midbrain for both membrane-bound 
and soluble isoforms of COMT protein expression at 6h and 1d (Figure 3). Administration of 
MG132 prior to CFA normalized reductions in COMT expression in midbrain. No differences in 
COMT expression were observed in forebrain, hindbrain or spinal cord tissue samples (data not 
shown).  
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Figure 4.3. CFA inflammation reduces COMT expression in rat midbrain via an NF-κB mechanism. 
Western blot analysis of COMT expression of both membrane-bound and soluble isoforms in rat 
midbrain lysates after intraplantar administration of CFA and MG132 prior to CFA. N=3/group. 
Data are mean + SEM. 
3.4 Constitutive activity of astrocytic NF-κB reduces COMT protein expression in mice 
Finally, we sought to determine if animals expressing astrocyte-specific IKKca exhibited 
altered COMT expression following CFA. Separate groups of IKKca and Co mice were 
administered CFA and tissue was collected at acute, subchronic and chronic time points from 
discrete pain-associated brain regions, spinal cord and dorsal root ganglia for COMT protein 
expression analysis. As the trends in COMT expression levels (for both membrane-bound and 
soluble isoforms) were similar according to brain region (e.g. hindbrain, midbrain and forebrain), the 
data were averaged in this manner. Analyses showed significant group differences in COMT 
expression between IKKca and Co mice in forebrain (t12=4.014, P<0.002) and midbrain (t12=3.676, 
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P<0.01). Specifically, similar to the results obtained in rats receiving the NF-κB inhibitor, IKKca 
mice exhibited significant decreases in COMT expression in midbrain (thalamus and hypothalamus) 
as well as in forebrain (nucleus accumbens and somatosensory cortex). We then assessed if there 
were significant differences at specific timepoints. Compared to Co mice, IKKca mice expressed 
significantly less COMT in forebrain at 1h (t12=3.10, P<0.003) (Figure 4A,B) and in midbrain at 1h 
(t11=3.04, P<0.01) and 1d (t12=3.14, P<0.008) post-CFA (Figure 4C,D).  
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Figure 4.4. CFA inflammation reduces COMT expression in forebrain and midbrain of IKKca mice.  
Western blot analysis and representative Western blots of COMT expression in mouse (A) forebrain 
and (B) midbrain tissues of IKKca and Co mice receiving CFA. N=3-4/group. Data are mean + 
SEM. *P<0.05. 
4. Discussion 
The present study employed pharmacologic and genetic approaches in an animal model of 
inflammation to examine the relationship between NF-κB, pain, and COMT expression. We found 
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that animals with inhibited NF-κB activity exhibited decreased CFA-induced pain, while those with 
enhanced astrocytic NF-κB activity exhibited increased CFA-induced pain. Furthermore, we provide 
the first systems-level demonstration showing that CFA-induced inflammation leads to reductions in 
COMT protein expression via an NF-κB mechanism.   
NF-κB is widely recognized as a master switch that is essential for immune responses. An 
emerging literature shows that NF-κB plays an important role in the central nervous system, where 
it can drive pain associated with injury and inflammation. For example, animals with p50 
knockout(Niederberger et al., 2007) or p65 knockdown(Luo et al., 2014) show reduced pain 
following administration of intraplantar formalin or intradermal CFA, respectively. CFA contains 
Mycobacterium tuberculosis, which can directly stimulate toll-like receptors-2 and -4, which in turn signal 
through MyD88 to stimulate various inflammatory cascades, including the NF-κB pathway. 
Administration of MG132, which induces upstream IκBα nuclear translocation to more fully block 
NF-κB-mediated transcription,(Vu et al., 2008) reduces pain following systemically-administered 
CFA. The present study extended these findings by testing the ability of MG132 to prevent the 
development of mechanical and thermal hypersensitivity following intraplantar CFA. Accordingly, 
we found that rats receiving a pre-emptive dose of MG132 exhibited reduced hypersensitivity to 
mechanical and thermal stimuli for the duration of the two-week testing paradigm.  
Based on evidence demonstrating that nociceptive stimuli induce NF-κB activity in 
astrocytes, we were particularly interested in understanding if astrocytic NF-κB signaling regulated 
CFA-induced pain. Astrocytic NF-κB regulates the expression of genes linked to immune responses, 
triggering the transcription of TNF-α, IL-1β and COX-2 (Niederberger et al., 2007). In turn, TNFα 
or IL-1β can increase the transmission of pain signals by directly lowering the activation threshold 
for nociceptors (Binshtok et al., 2008a, Gudes et al., 2015). Astrocytic NF-κB can also strengthen 
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plasticity-related events that increase the transmission of pain. For example, in a study assessing 
memory performance, mice expressing a dominant negative isoform of IκBα in astrocytes, thereby 
inhibiting astrocytic NF-κB activity, showed deficits in memory tasks that correlated with decreased 
expression of postsynaptic density protein 95 (PSD95) (Bracchi-Ricard et al., 2008). In the present 
study, we found that mice expressing a constitutively active form of IKK in astrocytes displayed 
increased pain in the CFA-injected ipsilateral paw that lasted throughout the duration of the two-
week testing paradigm. Interestingly, the IKKca mice also displayed increased mechanical allodynia 
and hyperalgesia in the unaffected contralateral paw beginning during the subchronic phase of 
injury. This may be a result of a phenomenon known as spreading (Radhakrishnan et al., 2003). It 
should also be noted, though, that repetitive mechanical stimuli, as used in this study, may result in 
increased activation of spinally-located second-order sensory neurons, possibly a result of temporal 
summation (Herrero and Cervero, 1996, Ringkamp et al., 1999). Given that IKKca and Co mice did 
not show significant differences in mechanical or thermal sensitivity at baseline or after IFA 
injection, a pro-inflammatory event, such as CFA administration, may be required for the emergence 
of a behavioral phenotype, in this case prolonged mechanical hypersensitivity. To our knowledge, 
this is the first gain-of-function study to demonstrate that enhanced astrocytic NF-κB activity 
prolongs the duration of inflammatory pain as well as its ability to spread contralaterally.  
While NF-κB can influence the transcription of genes involved in inflammation and 
plasticity, another gene that contains a known κB binding site is COMT. Following NF-κB induction 
by TNFα, binding of p65 to the known P2-COMT promoter in a human astrocyte cell line (H4 
cells) in vitro dampens COMT mRNA and protein expression (Tchivileva et al., 2009a). In line with 
these findings, we observed NF-κB-linked reductions in COMT expression at 6h and 1d following 
CFA in midbrain in rats and 1h and 1d following CFA in forebrain and midbrain in mice (Figure 5). 
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COMT expression likely was not downregulated during the entirety of the inflammation period 
because NF-κB activity is known to fluctuate during an inflammatory event (Gilmore, 2006). COMT 
expression in brain normalized at later stages of inflammation. Furthermore, inflammation-linked 
COMT expression in mice and rats is tissue- and, in this case, brain region-specific (Nissinen, 2010). 
At present, few studies have assessed how COMT expression is regulated, particularly in the brain. 
Genetic studies have predicted that promoters for the COMT gene contain binding motifs for 
transcription factors including Sp1, AP-2 and NF-D. Furthermore, altered COMT expression in 
brain has been associated with administration of mood stabilizing drugs, local infusions of 
inflammatory agents, as well as developmental vitamin D deficiencies (Nissinen, 2010). 
 90 
 
Figure 4.5. Schematic depicting how NF-κB mediated transcription of TNFα may regulate COMT 
expression.  
Our in vivo data, together with in vitro findings from Tchivileva et al., 2009, suggest an NF-κB-
dependent mechanism in which a pro-inflammatory stimulus such as TNFα or CFA can initiate NF-
κB, thereby permitting nuclear translocation of p65, which subsequently binds to the P2 promoter 
of COMT and prevents its transcription.  
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Reductions in COMT expression can increase pain sensitivity in both humans and animals. 
In humans, decreased COMT expression and/or activity as a result of genetic variance have been 
linked to increased susceptibility to temporomandibular joint disorders(Diatchenko et al., 2005) and 
fibromyalgia (Gursoy et al., 2003, Barbosa et al., 2012b). In animals, decreased COMT activity, as a 
result of pharmacological inhibition, increases pain sensitivity (Nackley et al., 2007, Kambur et al., 
2010). Heightened pain sensitivity persists after the cessation of COMT inhibitor administration, 
suggesting that even transient reductions in COMT expression, such as those observed in brain in 
this study, may result in heightened pain states (Hartung and Nackley, 2014). In addition to 
increasing pain sensitivity, decreased COMT activity also results in the release of pro-inflammatory 
molecules including TNFα, which is required for the development of COMT-dependent pain 
(Hartung et al., 2014). As discussed earlier, TNFα may also contribute to NF-κB activation and 
downstream alterations in COMT expression, thereby driving COMT-dependent pain. Indeed, these 
studies highlight the complexity of overlapping regulatory pathways that may be involved in the 
potentiation of pain and/or COMT expression.  
Here, we demonstrate that COMT protein expression is altered as a result of NF-κB- 
mediated inflammation. At present, drugs that block NF-κB activity, such as IκB inhibitors 
(Niederberger and Geisslinger, 2008), or indirectly block the initiation of NF-κB, such as the TNFα 
antagonist etanercept, are currently in use for individuals experiencing chronic pain conditions such 
as fibromyalgia and rheumatoid arthritis. Thus, future studies will assess how NF-κB and/or COMT 
play a role in mediating pain behaviors in other models of inflammatory and neuropathic pain. 
Given that sex differences appear to affect the etiology of inflammatory pain, it will also be 
important to test this relationship in females. 
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5. Conclusion 
This study highlights the role of NF-κB in regulating inflammatory pain and COMT 
expression in the CNS. Pharmacological inhibition (which quiets NF-κB activity) attenuates 
inflammatory pain, while constitutive activation of IKK in astrocytes (which enhances NF-κB 
activity) leads to lasting inflammatory pain. Negatively correlated with pain phenotypes, COMT 
expression was decreased in animals with greater NF-κB activity. This is the first demonstration that 
inflammation can influence COMT expression in the brain in an NF-κB-dependent method. 
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Supplementary Figure 4.1.  
Co and IKKca mice exhibit heightened (A) mechanical allodynia, (B) mechanical hyperalgesia, and 
(C) thermal hyperalgesia behaviors at 1h and 6h following IFA. There are no group differences in 
IFA-induced pain behavior, which resolves by day 1 or 3. Data are mean + SEM. 
 
 
 93 
 
 
 
Chapter 5. Discussion 
5.1 Summary 
5.1.1 Impact of Catecholamine Dysregulation on the Onset and Maintenance of Pain 
 Here, we report catecholamine dysregulation through COMT inhibition results in increased 
pain. This is driven through β2- and β3AR stimulation and downstream release of circulating pro-
inflammatory molecules including nitric oxide (NO) and innate immune cytokines (TNFα, IL-1β, 
IL-6 and CCL2). Blockade of either NO or TNFα, IL-1β, or IL-6 was able to prevent COMT-
dependent pain. Furthermore, nitric oxide and pro-inflammatory cytokines act in a feed-forward 
manner, such that increased NO results in increased cytokines and vice-versa. These studies 
represent the molecules and events involved in the onset of COMT-dependent pain. 
While this work proposes a possible mechanism by which pain is initiated, we also sought to 
understand the mechanisms involved in the maintenance of pain.  In order to assess this, we 
pharmacologically blocked COMT for 14 days and assessed pain and molecule release during and 
after COMT blockade. As our group has reported previously, we found that blockade of COMT for 
14 d led to increased mechanical allodynia and hyperalgesia, which lasted for 21 days following 
cessation of COMT antagonist administration. Notably, blockade of β2- and β3AR prevented the 
onset of pain, but did not reverse pain. These data suggest that while β2- and β3ARs are required for 
the onset of pain, they do not contribute to the maintenance of COMT-dependent pain.  
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Our group then sought to uncover the βAR-independent mechanisms of COMT-dependent 
pain. To do so, we chose to assess levels of various correlates of pain, including cytokines, cellular 
activation and mitogen activated protein kinases (MAPKs).  We found that increases in pain are 
associated with increased TNFα in CSF as well as increased phosphorylated p38 in the spinal dorsal 
horn. We also observed that ERK1/2 was increased on day 14 in DRG. In order to understand if 
MAPKs were required for the maintenance of pain, we administered a continuous intrathecal dose 
of either a p38 inhibitor or an ERK1/2 inhibitor beginning on day 14. We found that intrathecal 
administration of a p38 inhibitor on day 14 reversed COMT-dependent mechanical allodynia and 
mechanical hyperalgesia. While intrathecal administration of an ERK1/2 inhibitor reversed 
mechanical allodynia, it did not reverse mechanical hyperalgesia. Taken together, these data suggest 
that while the onset of pain may be regulated by previously identified β2- and β3ARs, extended 
dysfunction of catecholamine regulation may result in MAP kinase activation that drive pain (Figure 
5.1) 
 
Figure 5.1 Proposed model for the onset and maintenance of pain.  
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Distinct mechanisms underlie the onset of pain linked to catecholamine dysregulation, such that β2- 
and β3ARs are required for the onset of pain, while p38 contributes to the maintenance of pain. 
 
5.1.2 Role of the Immune System on Inflammatory Pain and COMT Protein Regulation 
While we looked specifically at the downstream effects of COMT inhibition on pain, we 
were also interested in understanding how COMT protein expression could be altered. Previous data 
conducted in vitro indicated that the expression of COMT could be altered based on TNFα-induced 
stimulation of NF-κB in astrocytes (Tchivileva et al., 2009a). We were interested if a similar 
phenomenon occurred in vivo, such that inflammatory stimuli would alter COMT protein expression 
via NF-κB. Therefore, we assessed if NF-κB activity stimulated by CFA could either increase or 
decrease COMT expression. We administered an intraplantar dose of CFA to the rat hindpaw in rats 
with NF-κB inhibition or in mice with NF-κB constitutive activity. In rats, we found that inhibition 
of NF-κB prevented CFA-induced pain as well as decreases in COMT expression in the forebrain. 
Oppositely, in mice, we found that constitutive activity of astrocytic NF-κB prolonged mechanical 
sensitivity and reduced expression of COMT protein expression compared to wildtype mice. Taken 
together, these data support the hypothesis that decreases in COMT expression elicited by 
inflammation are correlated with increased pain. Indeed, a wide variety of environmental factors can 
contribute to the differential expression of COMT (Tunbridge et al., 2006). As in our acute model, 
even transient decreases in COMT expression can result in increased pain and release of pro-
inflammatory molecules. This may be just one of many mechanisms by which COMT expression is 
altered downstream of an injury, infection, or after psychological distress. 
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Results indicate that there are COMT reductions in response to CFA and NF-κB 
constitutive activity in astrocytes. These results are interesting for a few reasons. First, these data 
suggest that NF-κB activity in astrocytes plays an important role in the prolongation of pain. At 
present, there is very little research assessing astrocyte-derived NF-κB in various pain modalities or 
in particular pain regions. Furthermore, there are few research groups that are actively assessing the 
roles of NF-κB in the central nervous system in neurological-related disorders. Some of these 
studies include those conducted by Kleinschmidt and colleagues, who suggest that NF-κB in 
neurons, particularly neurons in the forebrain (e.g. nucleus accumbens) may play an important role 
in depression and anxiety. These studies have been followed-up by Scott Russo’s group, showing 
that the IκB kinase can regulate social defeat stress (Christoffel et al., 2011). Indeed, social defeat 
stress has been shown to be regulated, at least in part, by stimulation of beta-adrenergic receptors 
(Wohleb et al., 2011). Given that inhibition of either NF-κB or βARs can give way to a reduction in 
stress, it would be worthwhile to assess if βAR stimulation prolongs the activation of NF-κB, and if 
this has a measurable behavioral effect. 
5.1.3 Integration of Observations  
Here, we find that the mechanisms and sites of action contributing to the onset and 
maintenance of COMT-dependent pain are distinct from one another. Taking these data together 
with recent findings in our group showing that COMT-dependent pain mechanisms originate in the 
periphery (Ciszek et al., 2016), a period of sustained COMT inhibition results in a shift to the central 
nervous system, whereby COMT-dependent pain is maintained. At present, we do not know the 
particular mechanisms that induce this shift from the periphery to the central nervous system. One 
possible mechanism is neurogenic neuroinflammation. In neurogenic neuroninflammation, a 
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hypernociceptive response paired with increased inflammation can trigger elevated release of pro-
inflammatory cytokines, activation of MAP kinases such as p38, and long term potentiation between 
peripheral nociceptor terminals and secondary afferents (Xanthos and Sandkuhler, 2014). Similar 
events can occur without inflammation: high levels of nociceptive activity in the periphery, such as 
through intraplantar capsaicin administration or neuropathic pain, can result in increased activation 
of ERK1/2 or p38, respectively (Ji et al., 2009), in the dorsal spinal horn. 
These increases in MAPKs, which can induce mechanisms related to sensitization (Ji et al., 
2009, Zhang et al., 2010), may prolong states of pain in the absence of injury or inflammation. This 
may explain why we observed sustained mechanical allodynia and hyperalgesia throughout the 
behavioral paradigm, even after the COMT inhibitor is no longer on board. Furthermore, because 
we did see that p38 inhibition was able to reverse COMT-dependent pain, this suggests that p38 
drives pain, while βAR signaling plays a lesser role in the maintenance phase. Data from these 
studies underscore the importance of peripheral inputs to the central nervous system that then affect 
the activity and expression of proteins in the central nervous system.  
Finally, we found that alterations in COMT expression can result in an increase in 
inflammation, and that similarly, inflammation may result in altered COMT expression. Given that 
there are known triggers that are linked to chronic pain conditions, initiation of this possible positive 
feedback loop may result in increased pain. While COMT is just one enzyme of many different 
molecules and processes that can alter sympathetic tone, it is clear that COMT plays a key role in 
driving pain while increasing acute inflammation and long-term sensitization. These data follow a 
line of evidence that shows that short term catecholamine dysregulation, such as an increase in 
epinephrine and norepinephrine, results in release of circulating inflammatory mediators if there is 
no pre-existing inflammation in that system (Szelenyi et al., 2006). Furthermore, because TNFα acts 
as a key regulator of COMT transcription (Tchivileva et al., 2009a), observed elevations in TNFα 
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following COMT inhibition may trigger a feed-forward mechanism such that TNFα acts to decrease 
local expression of COMT and thereby potentiate COMT-dependent pain. 
    
5.2 Future Directions 
Data collected from these studies have revealed a number of questions that necessitate study. 
This is by no means an exhaustive list of possible experiments, but an outline of those studies that 
are most important and/or interesting that should be conducted to better understand the 
mechanisms of pain elicited by catecholamine dysregulation. 
5.2.1 Determining the Complete Duration of COMT-Dependent Pain 
 While I followed rats with chronic COMT inhibition for 21 days following a 14 day 
administration of COMT inhibitor, we continued to observe that elevated mechanical pain 
throughout the behavioral paradigm. Future studies should follow rats given 14d of COMT inhibitor 
until pain ceases, if it does at all. By determining the length of time it takes for pain to resolve 
following COMT-inhibition, we may begin to assess if those mechanisms that delay resolution. In 
addition we can assess if animals in this latent pain stage respond differently (e.g. intensified and/or 
prolonged pain) or if they are more pain sensitive when given a stress challenge. 
5.2.2 Measuring the Excitability of COMT-Dependent Pain Nociceptors 
 One of the most important questions that our lab must answer is if peripheral nociceptor 
firing is increased downstream as a result of COMT-dependent pain. It is possible that nociceptors 
elicit action potentials at lower thresholds as a result of COMT-dependent pain, which was seen in a 
form of sensitization elicited by βAR activation (Khasar et al., 1999b). Work from these experiments 
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may reveal that peripheral nociceptors are more sensitized in the early stages of COMT-dependent 
pain, but that nociceptor sensitization subsides and gives way to more spinally located central 
sensitization at later stages. By determining whether or not nociceptor activation is altered, we can 
more easily understand the peripheral component of COMT-dependent pain. Furthermore, if we 
observe an initial difference in nociceptor excitability followed by no difference in COMT-
dependent pain, these observations may indicate a central sensitization mechanism. 
5.2.3 Locating Beta-Adrenergic Receptors on Peripheral Neurons 
 We find that βARs contribute to the onset, but do not play a role in the maintenance of 
COMT-dependent pain. However, it is unclear how βAR dynamics are altered as a result of COMT 
inhibition. The most straightforward hypotheses are that peripheral β2- and β3ARs are 
downregulated on pain relevant molecules or that the G-proteins associated with β2- and β3AR 
change during the transition from the onset to the maintenance of COMT-dependent pain. To 
address the first hypothesis, that the abundance of β2- and β3ARs are reduced after 7d of COMT 
inhibition, it would be important to measure the expression of β2- and β3ARs in pain relevant tissues. 
Because COMT-dependent pain appears to be maintained peripherally, it would be worthwhile to 
measure expression of β2- and β3ARs in dorsal root ganglia as well as nerve terminals using 
immunohistochemistry. In using immunohistochemistry in particular, we would be able to see where 
these receptors are going to be expressed on both cell bodies as well as nerve terminals. At present, 
there are few well-characterized antibodies that target either β2- or β3ARs, so alternatively, receptors 
could be labeled using an in situ hybridization probe specific for either the β2- or the β3AR transcript. 
To address the second hypothesis, that β2- and β3ARs switch their second messenger 
cascade downstream of pain, it may be important to assess βAR coupling using a co-
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immunoprecipitation to study the coupling of either β2- or β3ARs to the various Gα subunits in pain. 
Khasar and colleagues find that while βARs generally couple with Gαs, which increases cAMP 
production, chronic βAR activation results in Gα-I coupling, which decreases cAMP production 
(Khasar et al., 1999b). 
5.2.4 Assessing Tissue-Specific Dynamics of Cytokine Release and Immune Cell Abundance in Peripheral and 
Central Tissues in COMT-Dependent Pain Animals 
Previously, we found that COMT inhibition led to increases in pain and pro-inflammatory 
cytokines via β2- and β3AR activation.  While cytokine levels were elevated at 3h, we did not observe 
differences in circulating cytokines prior to this timepoint. This could be a result of a delay following 
the activation of immune cells or accumulation of released cytokines reaching detectable levels only 
as early as 3 h. In our studies, we observed increased levels of TNFα in cerebrospinal fluid at 14d, 
21d and 35d of our timeline. However, measuring cytokine release in either blood or cerebrospinal 
fluid does not account for tissue-specific release of cytokines, particularly to pain-relevant regions of 
the central nervous system. Therefore, it would be valuable to assess if there are changes in local 
cytokine secretion at the tissue level in DRG and spinal cord tissues from animals receiving the 
COMT inhibitor over time. 
Others have reported that elevated adrenergic signaling leads to increases in immune system 
derived cells that express transcripts encoding for pro-inflammatory cytokines (McIlvried et al., 
2016). Therefore, future work can determine if there are changes the abundance of cells and the 
proteins they secrete in peripheral and central nervous system tissue following COMT inhibition. 
One method in which this could be conducted is through use of a combination of flow cytometry 
and cell sorting. As such, immune-related cells would be sorted through from nervous system tissue 
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(DRG and spinal cord) and from blood. Here we would assess the abundance of immune cells 
located in nervous system tissue and blood during short-term and long-term OR486 administration. 
Given that we have observed increases in levels of cytokines in blood during the short term, we 
would predict to see increased levels of activated immune cells in blood during an acute timepoint 
(defined previously as <4h), while we would predict that the levels of myeloid cells in nervous 
system tissues would be elevated during longer time periods (>7d). Furthermore, once the subtypes 
of cells have been identified in these tissues, assessing cell-type specific mRNA transcript expression 
may reveal the mechanisms by which these immune cells directly or indirectly influence peripheral 
afferent activation or nociceptive processing. If indeed COMT inhibition alters the abundance and 
types of immune cells located in the periphery, then it may also be worthwhile to understand how 
the immune system responds to extended catecholamine dysregulation.  
5.2.5 Assessing the Role of Environmental Triggers on Genetically-Predisposed Animals  
One important feature that has yet to be explored is why COMT polymorphisms affect 
some individuals, leading to increased experimental and clinical pain (Diatchenko et al., 2005), while 
others remain unaffected. Based on Hardy-Weinberg ratios, it is estimated that approximately one-
third of individuals have the SNPs related to lower COMT expression and activity. However, not 
nearly as many individuals have one or more chronic pain conditions. One possible explanation for 
this discrepancy between the number of individuals with gene variants and those individuals with 
chronic pain is that the effects of genetic polymorphisms require one or more environmental 
triggers, such as injury or a repeated stressor (Diatchenko et al., 2006, McLean et al., 2011).  
In a laboratory setting, we see a similar phenomenon in mice as observed in humans. While 
mice that have complete knockout of COMT have significantly higher levels of mechanical and 
thermal hyperalgesia compared to their wildtype littermates, those animals that are heterozygous for 
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the COMT knockout gene (and that presumably express half the COMT compared to wildtype 
animals) do not display mechanical and thermal hyperalgesia, similar to their wildtype littermates 
(unpublished data from B.P Ciszek). The amount of COMT expressed by heterozygous mice is 
sufficient such that the animals do not have altered mechanical or thermal sensitivity. However, in a 
study conducted years earlier focusing on stress and anxiety, these COMT +/- heterozygotes display 
increased anxiety as measured by elevated internal temperature after handling, decreased time spent 
in the open arms of an elevated plus maze, and decreased time exploring novel objects (Papaleo et 
al., 2008). Given their altered responses to stressors, can stress alter COMT +/- mice pain 
phenotypes? For these experiments, we would measure baseline levels of pain sensitivity in COMT 
+/+, +/-, and -/- mice, expose these animals to a stressor such as swim stress or a three day 
paradigm of chronic variable stress, and measure pain behaviors 24 h following, thereby reducing 
the effects of stress analgesia. I would hypothesize that while all animals, regardless of genotype, 
would have an increase in pain sensitivity, those with the +/- genotype would have similar increases 
in pain sensitivity to the -/- mice, thereby uncovering the initially dormant phenotype. 
5.2.6 Assessing the Role of Sex in Mechanisms of COMT-dependent Pain  
 Because chronic pain conditions generally affect women with much greater frequency than 
men, it is necessary to begin assessing how chronic pain is driven in females. Up to this point, while 
behavioral assessments with the COMT-dependent pain model show no sex-dependent differences 
in the initiation of pain (Ciszek et al., 2016), molecular studies have been limited exclusively to males. 
However, recent evidence from the Mogil lab suggests an alternative mechanism of 
neuroinflammation: in female rodents, chronic neuropathic pain is not driven by microglia but by T-
cells (Sorge et al., 2015). While our pain model is different from neuropathic pain, this finding 
highlights the importance of conducting studies that incorporate both males and females, as we may 
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observe similar differences in cellular activation in our own COMT-dependent pain model. 
Therefore, replicating these COMT-dependent studies in female rodents may be important to 
revealing the unique mechanisms that may trigger and potentiate pain more commonly in females. 
 One way in which we may see differences in males and females is through activation of p38. 
Evidence presented by the Ji group demonstrates that there are sex-specific differences in the role of 
spinal p-p38 in some types of inflammatory and neuropathic pain. In this study, Taves and 
colleagues report that p38 phosphorylation was more pronounced the spinal dorsal horn 
downstream of neuropathic pain in males, but not in females. Furthermore, intrathecal 
administration of p38 inhibitor prevented formalin-induced pain and reversed neuropathic 
constriction injury pain in male mice and rats, but was not effective for female rodents (Taves et al., 
2015). While we have observed increases in spinal p-p38 in males as well as reversal of COMT-
dependent pain in males, we have not yet looked to see if these findings are the same in females. 
Therefore, future work should assess pain behaviors and molecular changes, including p38 activation, 
occurring in both females and males. 
5.2.7 Overexpressing COMT in Neuropathic and Inflammatory Pain Models 
Data from our NF-κB studies suggest that reductions in COMT are associated with 
increases in mechanical pain sensitivity. These data indicate that COMT may play an important role 
in the induction of inflammatory pain, such that decreases in its expression may be important in the 
chronicity of pain. Based on these studies, it may be useful to see if overexpression of COMT in the 
forebrain, where we found the greatest reductions in COMT expression following CFA 
injection(Hartung et al., 2015)(Hartung et al., 2015)(Hartung et al., 2015)(Hartung et al., 
2015)(Hartung et al., 2015)(Hartung et al., 2015)(Hartung et al., 2015)(Hartung et al., 2015) (Hartung 
et al., 2015), can prevent or reduce some of the effects of inflammatory or neuropathic pain. COMT 
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overexpression will be driven with a Camk2a promoter, leading to the greatest increases in COMT 
expression in the forebrain. These CaMK2a-COMT mice have previously been used in the context 
of learning and memory (Simpson et al., 2014), but given their direct links to our lab’s work with 
COMT, may be an important tool to demonstrate a converse concept: that overexpression of 
COMT prevents increases in pain. Future studies using a mouse that overexpresses COMT and 
administering various types of well-known pain inflammatory and neuropathic pain models may 
reveal how COMT expression plays a key role in either the induction or the prolongation of pain. 
Results from these experiments could have interesting results, since overexpression of COMT 
would lower the availability of norepinephrine and thereby reduce the effects of possible descending 
input from α-adrenergic receptors. Indeed these experiments would require the need to measure 
levels of local catecholamines in the forebrain, measure mechanical and thermal pain in COMT 
overexpressers compared to their wildtype littermates, assess if the COMT overexpressers display 
altered pain behavior responses (either increased or decreased) in different models of inflammatory 
and/or neuropathic pain, and ultimately determine if α- and/or β-adrenergic receptors play an 
important role in the inhibition or facilitation of pain signals. 
5.3 Conclusions 
 The aims of this dissertation were developed as a means to better understand how long-term 
catecholamine dysregualtion leads to pain that last weeks following its onset. These studies indicate 
that distinct mechanisms underlie both the onset and maintenance of COMT-dependent pain, 
adding to a growing body of evidence now indicating that that the transition to chronic pain includes 
a sequence of events in which the maintenance of pain is nearly independent of what is required its 
induction. These studies suggest that catecholamine dysregulation is sufficient to induce long-term 
changes in pain, as observed in patients suffering from post-traumatic stress disorder or stress-
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related trauma, two patient groups that are often diagnosed with increased pain sensitivity, either 
following an injury or without any visible tissue damage. Third, given that these studies more closely 
mimic what is observed in patient populations (e.g. decreased COMT expression), research using 
this model may be useful in the development of either future clinical studies looking to find 
differences in particular molecular targets in chronic pain patients or to develop pharmaceuticals that 
target particular molecules depending on the patients chronic pain “phase,” the duration of time that 
the patient has exhibited heightened pain. As the field of pain research continues to grow, it will 
certainly be important to better characterize and address a number of issues that contribute to 
chronic pain: the different categories of pain, the length of time an individual has experienced 
symptoms, their genetic and experiential background, and their sex. Taking these factors wholly, we 
may find treatments that are more effective for patients that suffer from chronic pain. 
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